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Abstract 
Mechanisms underlying the cutaneous vasodilation response to local skin heating and 
whole body heating in humans remain unresolved. Although nitric oxide (NO) is known to 
contribute to these responses, it remains unclear as to the source of NO. Adenosine receptors 
induce vasodilation in many human tissues and may work, in part, through NO. As these 
receptors are also known to be located in the cutaneous vasculature, the studies contained in this 
thesis were designed to investigate a potential contribution of adenosine receptor activation to 
the rise in skin blood flow elicited by local skin and whole body heating. 
The study presented in chapter IV was designed to determine a potential role for 
adenosine receptors in contributing to cutaneous thermal hyperemia. Four cutaneous 
microdialysis sites were randomly assigned one of four drug treatments designed to elucidate the 
contribution of A1/A2 adenosine receptors during local skin heating. Each site was locally heated 
from a baseline temperature of 33°C to 42°C at a rate of 1°C/10 s and skin blood flow was 
monitored via laser-Doppler flowmetry (LDF). The data obtained from these experiments 
suggest A1/A2 adenosine receptor activation directly contributes to cutaneous thermal hyperemia. 
These data further suggest a portion of the NO response may be explained by A1/A2 adenosine 
receptor activation; however, a substantial portion of the NO response is independent of the 
adenosine receptor contribution. 
The study presented in chapter V was designed to determine a potential role for A1/A2 
adenosine receptors in contributing to cutaneous active vasodilation. Four cutaneous 
microdialysis sites were randomly assigned one of four drug treatments, as above, and skin blood 
flow was monitored via LDF. Whole body heat stress, sufficient to raise oral temperature at least 
0.8°C above baseline, was induced via water-perfused suits.  The data obtained from these 
  
experiments suggest A1/A2 adenosine receptor activation does not directly contribute to 
cutaneous active vasodilation; however, a role for A1/A2 adenosine receptor activation is 
unmasked when NO synthase is inhibited.  The data from this study further suggest that A1/A2 
adenosine receptor activation may be responsible for a portion of the known NO component of 
cutaneous active vasodilation. 
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Chapter 1 - Introduction 
 Statement of the Problem 
Regulation of human skin blood flow serves to protect the skin and core from extreme 
temperatures. Skin blood flow is increased in response to an increase in local skin temperature 
and an increase in core body temperature; however, the mechanisms governing these responses 
differ. The cutaneous vasodilation elicited by increases in local skin temperature, known as 
thermal hyperemia is mediated primarily by sensory nerves. This thermal hyperemic response 
protects the skin by moving the heat away from the heated area of the skin. In response to an 
increase in core body temperature, by contrast, humans exhibit a substantial increase in skin 
blood flow mediated by a sympathetic cholinergic active vasodilator system. This cutaneous 
active vasodilation along with a concurrent increase in sudomotor activity serves to increase heat 
loss to the environment, and is the primary autonomic means by which humans defend against 
increasing core temperatures.   
The precise mechanisms mediating thermal hyperemia and active vasodilation are not yet 
fully understood. As such, the studies contained in this thesis aimed to provide a better 
understanding of the mechanisms mediating each of these responses. Specifically, the study 
described in Chapter IV of this thesis was designed to investigate a potential role for A1/A2 
adenosine receptor activation in thermal hyperemia. The study described in Chapter V was 
similarly designed to investigate a role for A1/A2 adenosine receptor activation in cutaneous 
active vasodilation. 
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 Background 
Thermal hyperemia, induced by local heating of the skin, is mediated in part by sensory 
nerves.  Rapid, nonpainful, local heating of human skin elicits a thermal hyperemic response that 
is biphasic and characterized by a rapid rise in skin blood flow to an initial peak, followed by a 
brief nadir, and, finally, a more slowly established and prolonged plateau (Kellogg et al. 1999; 
Minson et al. 2001).  The initial peak and nadir of cutaneous thermal hyperemia have been 
shown to be primarily mediated by an axon reflex via activation of transient receptor potential 
vanilloid type 1 (TRPV-1) channels located on C-fiber afferent neurons (Magerl and Treede, 
1996; Minson et al. 2001; Wong & Fieger, 2010), and a modest contribution from nitric oxide 
(NO) (Kellogg et al. 1999; Minson et al. 2001). The secondary plateau phase of the local heating 
response, by contrast, consists of a sustained increase in skin blood flow that is approximately 
70% dependent on NO (Minson et al. 2001). The sensory nerves involved may elicit vasodilation 
through the release of substance P and/or calcitonin gene-related peptide (CGRP).  A recent 
study by Wong and Minson (2011) suggests neurokinin-1 (NK1) receptors, which preferentially 
bind substance P, are involved in the thermal hyperemic response; however, direct evidence for 
substance P and/or CGRP is currently not available. Questions remain as to the mechanisms 
mediating thermal hyperemia and what other vasodilator substances may be involved. 
Thermoregulatory skin blood flow, elicited by alterations in core body temperature, is 
uniquely controlled by a sympathetic adrenergic vasoconstrictor system and a sympathetic 
cholinergic active vasodilator system (Grant and Holling, 1938; Roddie et al.1957).  The 
cutaneous vasoconstrictor system is tonically active, regulating subtle alterations in skin blood 
flow during periods of normothermia as well as causing increased cutaneous vasoconstriction 
during exposure to cold stress (Grant and Holling, 1938). As core temperature rises during heat 
stress, an initial rise in skin blood flow occurs via withdrawal of sympathetic adrenergic 
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vasoconstriction. With a further increase in temperature to a specific core temperature threshold, 
reflex cutaneous active vasodilaton occurs, concurrent with the onset of sweating (Grant and 
Holling, 1938; Roddie et al. 1957). The resulting increase in skin blood flow moves heat from 
the body’s core to the periphery where heat is lost via convection from the blood to the 
environment through the skin. The simultaneous increase in sweating allows for evaporative heat 
loss and regulation of normal core body temperature.  
The active vasodilator system is known to be mediated by sympathetic cholinergic nerves 
and is responsible for both the sweat and skin blood flow responses (Grant and Holling, 1938; 
Roddie et al. 1957; Fox and Hilton, 1958; Kellogg et al. 1995). By the current co-transmission 
theory, acetylcholine is released from sympathetic nerves and primarily mediates the sweat 
response, while cutaneous vasodilation is mediated by unknown co-transmitter(s) (Kellogg et., 
1995). Additionally, nitric oxide (NO) has been shown to directly mediate 30-45% of this 
process and is required for full expression of active vasodilation (Kellogg et al. 1998; Shastry et., 
1998; Wilkins et al. 2003). The co-transmitter(s) released from sympathetic vasodilator nerves to 
directly mediate cutaneous vasodilation and/or promote the production of NO remain unknown. 
A1 and A2 adenosine receptors have been found to be located in the human skin 
microcirculation (Stojanov and Proctor, 1989) and activation of these receptors has been shown 
to mediate vasodilation in multiple organ systems (Abebe et al. 195l; Ray and Marshall 2009; 
Stojanov and Proctor, 1989).  Microdialysis infusion of adenosine into the interstitial space of 
human skin has been shown to elicit vasodilation to an extent similar to that achieved during 
whole body heating (Shibaski et al. 2007). Furthermore, adenosine receptors have been shown to 
induce vasodilation, at least in part, by increasing NO production (Mortensen et al. 2009; Stewart 
et al. 2004; Vials and Burnstock, 1993).  The studies described in Chapters IV and V were 
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designed based on this rationale to investigate a potential role for A1 and A2 adenosine receptors 
in the thermal hyperemic and cutaneous active vasodilator responses, respectively. 
 Specific Aims 
The studies discussed in this thesis were designed to address the following specific aims: 
 
1. The purpose of the study presented in chapter IV of this thesis was to investigate a 
potential A1/A2 adenosine receptor-mediated component to the cutaneous thermal hyperemic 
response. Additionally, this study aimed to determine whether a portion of the NO-dependent 
component of this response may be explained by adenosine receptor activation. 
2. The purpose of the study presented in Chapter V of this thesis was to determine 
whether adenosine receptor activation contributes to reflex cutaneous active vasodilation. 
Additionally, this study aimed to determine whether a portion of the NO component of cutaneous 
active vasodilation might be explained by A1/A2 adenosine receptor activation. 
 Hypotheses 
The studies presented in this thesis were designed to test the following two hypotheses: 
 
1. The study described in Chapter IV was designed to test two main hypotheses. We 
hypothesized adenosine receptor blockade would result in an attenuated plateau response to local 
heat application. We further hypothesized simultaneous blockade of adenosine receptors 
combined with NOS inhibition would result in a greater attenuation of the NO-dependent 
secondary plateau. 
2. The study described in Chapter V was designed to test two hypotheses. We 
hypothesized a direct role for adenosine receptor activation would be suggested by an attenuation 
of the skin blood flow response to heat stress in the presence of the non-selective A1/A2 
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adenosine receptor antagonist theophylline. In addition, we hypothesized A1/A2 adenosine 
receptor inhibition combined with NO synthase inhibition would further attenuate this response, 
which would suggest adenosine receptor activation may also contribute to cutaneous active 
vasodilation through the production of NO. 
 Limitations 
1. Based on the experimental approach of the studies described in Chapters IV and V, we 
can only discuss the data in terms of A1/A2 adenosine receptor activation and not adenosine, per 
se, being involved in cutaneous thermal hyperemia and active vasodilation. Although adenosine 
is the most likely candidate to bind to, and activate, the A1/A2 adenosine receptors, the present 
data suggest an indirect role for adenosine, per se, and we cannot rule out the possibility that 
some other substance(s) bind to, and activate, the A1/A2 adenosine receptors.   
2. In Chapters IV and V the use of theophylline, a competitive but non-selective inhibitor 
of A1 and A2 adenosine receptors, does not allow us to determine the specific contribution of the 
various isoforms of adenosine receptors to cutaneous thermal hyperemia and active vasodilation.  
Both A1 and A2 adenosine receptors have been localized in human skin (Stojanov and Proctor, 
1989) and both isoforms have been shown to elicit vasodilation (Bryan and Marshall, 1999); 
however, it is difficult to determine and assign specific roles to each isoform and subtype as the 
distribution and mechanism of action is heterogeneous. Further complicating the matter is that 
selective adenosine receptor antagonists approved for human use are lacking.  As such, we chose 
to use a competitive, but non-specific, A1/A2 adenosine receptor antagonist. 
3. A 4 mM dose of theophylline was the maximum dose that could be administered via 
microdialysis in these studies without causing non-specific vasodilation.  In preliminary 
experiments, concentrations higher than 4 mM resulted in substantial vasodilation, which would 
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have influenced and made interpretation of the results of this study difficult. The increase in 
baseline skin blood flow observed with higher concentrations of theophylline is most likely due 
to the phosphodiesterase inhibitor properties of theophylline, which would act to increase cAMP 
levels and result in smooth muscle relaxation (Taddei et al. 1991). Due to this effect of higher 
doses of theophylline on baseline skin blood flow, we chose to use a 4mM dose. Our data clearly 
indicate a direct role for A1/A2 adenosine receptor activation to cutaneous thermal hyperemia as 
well as a possible source of NO; however, it is possible our data underestimate the contribution 
of A1/A2 adenosine receptor activation to cutaneous thermal hyperemia. 
7 
 
Chapter 2 - Review of the Literature 
 Sensory Nerves and Axon-Reflex Mediated Vasodilation 
 in the Cutaneous Vasculature 
The cutaneous vasodilation resulting from direct heat application to the skin is mediated 
by cutaneous sensory nerves and an axon reflex mechanism. An initial discussion of an axon 
reflex in the cutaneous vasculature was presented by Bayliss in 1901, based on the finding that 
cutaneous vasodilation could be elicited by stimulation of the peripheral end of a dorsal root 
primary afferent nerve, after the nerve had been cut. As cutting the afferent nerve would have 
prevented the transmittal of sensory information to efferent ventral nerves, the end-organ 
response of cutaneous vasodilation was unexpected. To explain these findings, Bayliss (1901) 
suggested that the observed vasodilation resulted from a signal traveling down afferent nerves in 
an efferent direction, a phenomenon he termed antidromic vasodilation. Further, evidence of 
sensory nerve innervation in the cutaneous circulation was cited to propose that sensory nerves 
and an axon reflex might mediate this cutaneous vasodilation. 
Subsequent studies supported the occurrence of axon reflex mediated vasodilation in the 
cutaneous circulation. Lewis and Grant (1924) and Lewis (1927) demonstrated that the flare 
reaction of local skin injury was prevented from spreading to nearby skin sites on which 
anesthesia was applied. Based on these results, these authors suggested that the flare response 
was mediated by an axon reflex, with a network of axons branching off of the afferent nerve 
being contained in the cutaneous circulation. Figure 2-1, below illustrates an axon reflex in the 
cutaneous cutaneous circulation, activated by a thermal stimulus. 
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Figure 2-1: Schematic Drawing of the Axon Reflex in Human Skin. 
 
 Mechanisms of Cutaneous Thermal Hyperemia 
The direct application of heat to human skin is known to elicit cutaneous vasodilation. As 
early as 1911 Hewlett et al. reported increased blood flow in response to skin heating. 
Subsequent studies found that infrared radiation of an area of skin elicited cutaneous vasodilation 
that was capable of spreading to nearby areas of skin, similar to the spread of the flare response 
due to local skin injury (Cooper, 1950; Crockord and Hellon, 1959). Due to the simultaneous 
timing of the vasodilation in radiated and irradiated areas of the skin, Crockford and Hellon 
(1959), concluded that a neural mechanisms was responsible for initiating the observed 
cutaneous vasodilation; however, it remained unknown whether this neural mechanism involved 
the central nervous system or was an axon reflex. Alternatively, these authors later suggested a 
theory of electronic coupling as a mechanism by which vasodilation may spread to nearby 
regions of skin.  
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Following a several year gap in the literature, several studies provided strong evidence of 
axon-reflex mediated cutaneous vasodilation in response to skin heating. One such study was 
presented by Magerl and Treede in 1996. These authors recorded changes in skin blood flow via 
laser-Doppler flowmetry at varying distances from a point of local heat application to the skin. 
Data from this study demonstrated cutaneous vasodilation which occurred between 8 and 30mm 
away from the site of heat application. As the length constant of vascular electronic coupling is 
approximately 1-2mm, these data suggested another mechanism, such as an axon reflex, must be 
involved to mediate cutaneous vasodilation at sites farther from the application of heat.   
More recently, Minson et al (2001), established that nonpainful heat application to 
nonglabrous human skin produces a biphasic thermal hyperemic response. This consistently 
produced response is characterized by a rapid rise in skin blood flow to an initial peak and nadir, 
attributed to an axon reflex,  followed by a more slowly established and prolonged plateau 
(Kellogg et al. 1999; Minson et al. 2001). A series of experiments by Minson et al. (2001), which 
will be explained in more detail below, revealed that independent mechanisms mediate the two 
phases of this response. As demonstrated by these studies, the initial peak and nadir of cutaneous 
thermal hyperemia is primarily mediated by an axon reflex, while the more slowly formed and 
prolonged rise in skin blood flow is primarily mediated by NO. Figure 2-2, below represents this 
characteristic skin blood flow response to rapid, nonpainful direct heating of human skin. 
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Figure 2-2: Representative Tracing of the Cutaneous Thermal Hyperemic Response. 
 
 As previously stated, the initial peak and nadir of the thermal hyperemic response are 
currently attributed to an axon reflex mechanism. As demonstrated by Minson et al. (2001), the 
initial peak and nadir components of the thermal hyperemic response are significantly attenuated 
when EMLA cream (topical anesthetic; 2.5% lidocaine and 2.5% prilocaine) is used to prevent 
the axon reflexes, while antebrachial nerve blockade does not alter this response. In this same 
study, the initial peak and nadir responses were also attenuated by NO synthase inhibition and 
further attenuated by combined NO synthase inhibition and EMLA cream. The attenuation 
resulting from combined NO synthase inhibition and EMLA cream, however, was not greater 
than that achieved by EMLA cream alone.   Moreover, recent data from Wong & Fieger (2010) 
suggests that activation of TRPV-1 channels are required for full expression of the initial peak 
and activation of TRPV-1 channels, by heat, on sensory nerves may be responsible for 
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depolarization of cutaneous sensory nerves.  Taken together, these data provide strong evidence 
that the initial peak and nadir components of skin blood flow response to local heating are 
mediated by an axon reflex, and nitric oxide contributes modestly to this response (Minson et al. 
2001).  
It has been suggested that the neuropeptides substance P and CGRP are involved in the 
axon reflex-mediated component of cutaneous thermal hyperemia.  Specifically, the direct 
application of heat to the skin may stimulate the release of these substances from heat-sensitive 
C-fiber afferent nerves in human skin to mediate the axon reflex component of cutaneous 
thermal hyperemia. Substance P and/or CGRP are the most likely candidates as these have been 
shown to be involved in axon-reflex mediated vasodilation.  A recent study by Wong & Minson 
(2011) demonstrates the desensitization of NK1 receptors significantly alters the thermal 
hyperemic response and indirectly suggests substance P is involved in cutaneous thermal 
hyperemia; however, a role for these substances in the axon reflex component of cutaneous 
thermal hyperemia has not been directly investigated. Thus, while the initial peak and nadir 
components of the thermal hyperemic response have been shown to be mediated by an axon 
reflex, the neuropeptides involved in this process have not been specifically identified. 
In contrast to the axon reflex component of thermal hyperemia, the secondary plateau 
phase of the local heating response consists of a sustained increase in skin blood flow that is 
largely dependent on NO, where inhibition of NO synthase greatly attenuates the plateau phase 
of thermal hyperemia (Kellogg et al. 1999; Minson et al. 2001).  These studies have determined 
that nitric oxide contributes approximately 70% to the secondary plateau phase of thermal 
hyperemia in the skin. Kellogg and colleagues (2009) have recently provided evidence to suggest 
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endothelial NOS (eNOS) may be the NOS isoform responsible for the NO-dependent secondary 
plateau.  
It remains unclear, however, as to the source of NO or what may stimulate the increase in 
eNOS activity during the local heating skin blood flow response. The contributions of H1 
receptor activation and the COX-1/COX-2 pathways to cutaneous thermal hyperemia have 
recently been investigated in independent studies (McCord et al. 2006; Wong et al. 2006).  
Inasmuch as these studies have demonstrated a minimal role for H1 receptor activation (Wong et 
al. 2006) and no role for COX-1/COX-2 activation (McCord et al. 2006) to cutaneous thermal 
hyperemia, it appears these pathways are not sources of NO during local heating.  Although there 
are likely to be several redundant vasodilator pathways involved in mediating cutaneous thermal 
hyperemia, important questions remain as to what substances may be involved in this response, 
either as a direct vasodilator or by increasing NO production.  
 Sympathetic Nerves and the Cutaneous Vasculature 
Thermoregulatory control of the cutaneous circulation is uniquely accomplished via dual 
innervation from the sympathetic nervous system. These two branches of the sympathetic 
nervous system in human skin regulate an adrenergic vasoconstrictor system and a sympathetic 
cholinergic active vasodilator system. Sympathetic adrenergic vasoconstrictor nerves release 
norepinephrine and the co-transmitter neuropeptide Y to result in vasoconstriction of cutaneous 
arterioles. By contrast, acetylcholine and one or more co-transmitters are released from 
cholinergic active vasodilator nerves. Each of these systems contribute to thermoregulatory 
control of skin blood flow as illustrated in Figure 2-3.  
13 
 
 
Figure 2-3: Schematic Illustrating Thermoregulatory Control of Skin Blood Flow. 
 
The activity of these two systems regulates skin blood flow, and ultimately maintains 
core body temperature during different environmental conditions. Under resting normothermic 
conditions, the adrenergic vasoconstrictor system remains tonically active to regulate subtle 
alterations in skin blood flow and maintain vascular tone (Grant and Holling, 1938). Upon 
exposure to cold, the activity of this vasoconstrictor system is increased to elicit a higher degree 
of cutaneous vasoconstriction. The resulting decrease in skin blood flow shunts blood flow to the 
periphery, reducing the loss of the body’s heat to the environment (Stephens et al. 2000). Upon 
exposure to a warm environment, by contrast, vasoconstrictor tone is withdrawn.  The resulting 
vasodilation approximately doubles skin blood flow compared to normothermic conditions, and 
increases the dissipation of heat from the blood to the environment. (Roddie et al. 1957). 
With a further increase in temperature to a specific core temperature threshold, reflex 
cutaneous active vasodilaton and sweating occur (Roddie et al. 1957; Kellogg et al. 1995).  The 
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resulting increase in skin blood flow moves heat from the body’s core to the periphery where 
heat is lost via convection from the blood to the environment through the skin. The simultaneous 
increase in sweating allows for evaporative heat loss and further maintenance of normal core 
body temperature. This active cutaneous vasodilation and increase in sudomotor activity are the 
primary autonomic means by which humans defend against increasing core temperatures. 
Mechanisms of Cutaneous Active Vasodilation 
Documented evidence that skin blood flow is under thermoregulatory control, dates as 
early as 1900. A study by Hough (1900), documented observed changes in venous size in the 
hand, during exposure to a range of external temperatures.  Hough reported increased skin blood 
flow in response to high external temperature, providing the earliest known documentation of 
thermoregulatory cutaneous vasodilation.   
Subsequent studies provided evidence that increases in blood flow in response to heat 
challenges, may be reflexively mediated by sympathetic nerves. Gibbon and Landis (1932) 
demonstrated that immersion of the upper extremities in warm water produced vasodilation in 
the lower limbs. Furthermore, in the same study, occlusion of the heated limb was found to delay 
the appearance of vasodilation in the opposite limb, leading to the conclusion that the return of 
heated blood from the warmed extremity was the stimulus for vasodilation in the opposite limbs. 
This study corroborated the findings of a 1931 study by Lewis and Pickering, which further 
showed that vasodilation was prevented in a sympathectomized limb. Several later studies 
confirmed the involvement of sympathetic nerves in this response (Grant and Holling, 1938; 
Grant and Pearson, 1938; Barcroft et al, 1943). Together, these findings demonstrated that 
thermoregulatory increases in blood flow may be reflexively mediated by sympathetic nerves. 
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This observed vasodilation was subsequently attributed specifically to the cutaneous 
circulation. Using various measurement techniques, several studies showed that the increase in 
blood flow was confined to the skin with no involvement of underlying muscle (Cooper et al. 
1954; Barcroft et al. 1955; Edholm et al;, 1956, Roddie et al. (1956). With the results of these 
studies, the cutaneous vasculature was identified as a major effector of thermoregulatory 
reflexes. 
The contributions of the vasoconstrictor and vasodilator nerves to this thermoregulatory 
reflex were later determined. Roddie et al. (1957) provided evidence that the increase in skin 
blood flow in response to increased core temperature involved both a withdrawal of 
vasoconstriction and activation of the vasodilator nerves. Blood flow through the forearm was 
measured via venous occlusion plethysmography during an initial whole body cooling followed 
by a transition to whole body heating. During the transition to whole body heating, a small initial 
increase in blood flow occurred. This initial increase in blood flow was found to be similar in 
magnitude to that reported previously when the vasoconstrictor nerves in the skin have been 
blocked (Barcroft, 1943), and was not prevented by intra-arterial administration of atropine. As 
demonstrated by this study by Roddie et al. (1957), the initial increase in blood flow was 
followed by a larger and more rapid increase in skin blood flow that occurred simultaneous with 
the onset of sweating. The administration of intra-arterial atropine was found to delay this large 
increase in blood flow and abolish the sweat response. Taken together, these results led to the 
following conclusions: 1) during exposure to environmental heat, an initial increase in skin blood 
flow occurs due to the release of vasoconstrictor tone, and 2) the subsequent large increase in 
skin blood flow is linked to the onset of sweating and is mediated by cholinergic nerves.   
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A co-transmission theory has recently been proposed to explain the mechanisms 
mediating cutaneous active vasodilation, as well as the link between cutaneous vasodilation and 
the sweat response. By this theory, acetylcholine is co-released with other substances from 
sympathetic cholinergic nerves. Acetylcholine then primarily mediates the sweat response, while 
the involved co-transmitters are primarily responsible for mediating cutaneous vasodilation, as 
illustrated in Figure 2-4. Strong experimental evidence for this theory was provided by Kellogg 
et al. (1995). In this study, the use of botulinum toxin to presynaptically block cholinergic 
vessels prevented both cutaneous vasodilation and the sweat response, suggesting that cutaneous 
vasodilation and sweating are both mediated by sympathetic cholinergic nerves. As stated above, 
the use of atropine abolishes only the sweat response. Together, these data suggest that 
acetylcholine and one or more neurotransmitters are co-released from sympathetic cholinergic 
nerves to mediate the sweat response and cutaneous active vasodilation, respectively.  
 
 
Figure 2-4:Co-transmission theory of Cutaneous Active Vasodilation. 
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Several substances have been proposed as potential co-transmitters involved in active 
vasodilation. One study by Bennet et al. (2003), suggested a possible role for the neuropeptide 
vasoactive intestinal polypeptide (VIP) in the skin blood flow response to whole body heating. 
These findings, however, have not been confirmed by subsequent studies (Wilkins et al. 2005). 
As such, a potential role for VIP in this response remains undetermined, and the identities of 
possible co-transmitters involved in cutaneous active vasodilation remain unknown. 
 In addition to the unknown co-transmitters involved in active vasodilation, a substantial 
role for NO has also been demonstrated in the response. Taylor and Bishop (1993) provided 
evidence of a role for nitric oxide, using the rabbit ear as a model for active vasodilation. In this 
study, NO synthase inhibition was found to abolish active vasodilation in the rabbit ear. One 
study by Dietz and colleagues (1994) was unable to determine a role for NO the active 
vasodilation occurring in human skin; however, using different experimental methods, several 
later studies have found that NO accounts for approximately 45% of reflex active vasodilation 
(Kellogg et al. 1995; Shastry et al. 1998). 
 Originally, this known role for nitric oxide in cutaneous active vasodilation was proposed 
to be permissive. Again, using the rabbit ear as a model for active vasodilation, Farrell and 
Bishop (1995), investigated the nature of the role for NO in this response. After blocking the 
production of NO in the rabbit ear, these investigators found that a low-dose infusion of the NO 
donor nitroprusside, given during hyperthermia, fully restored the blood flow response. By 
contrast, the same infusion of nitroprusside given during normothermia had no effect on blood 
flow in the rabbit ear. Given that the effects of nitroprusside were confined to the hyperthermic 
condition, and the hyperthermic blood flow response  was fully restored by only a low-dose 
infusion of an NO donor, these investigators determined that NO held a permissive role in active 
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vasodilation. In other words, only a basal level of NO was believed to be required for full 
expression of active vasodilation. 
In human skin, however, NO has since been found to contribute in a direct, rather than 
permissive manner to active vasodilation. In direct contrast to the findings of Farrel and Bishop 
(1995) in the rabbit ear, Wilkins et al. (2003) found that a low dose of exogenous NO in humans 
did not restore the skin blood flow response to whole body heating in microdialysis sites pre-
treated with an NO synthase inhibitor. Furthermore, Kellogg et al. (2003) measured an increase 
in the concentration of NO in human skin during cutaneous active vasodilation. An increase in 
NO concentration would not be expected if NO was permissive in this response. These studies 
provide strong evidence that NO directly contributes to cutaneous active vasodilation.  
While NO has been found to directly contribute by approximately 45% to the increase in 
skin blood flow during whole body heating, questions remain as to the source(s) of NO during 
this response. Kellogg and colleagues (2009) have recently provided evidence to suggest 
neuronal NO synthase (nNOS) may be the NO synthase isoform responsible for mediating NO 
generation during cutaneous active vasodilation. As nNOS inhibition, but not endothelial NO 
synthase inhibition, attenuates the skin blood flow response to whole body heat stress, this 
suggests a role for nNOS in this response.  
Several possible sources may contribute to increased NO generation by nNOS during 
active vasodilation. Shibaski et al (2002) found acetylcholine may contribute to NO synthesis; 
however, this contribution appears to be isolated to the early stages of heat stress, where 
acetylcholine may not be a significant source of NO once significant vasodilation has occurred. 
Additionally, while H1 histamine receptor activation and NK1 receptor activation have both been 
shown to directly mediate a portion of the cutaneous vasodilation during hyperthermia, evidence 
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suggests these receptor types may also contribute to the NO component (Wong et al. 2004; 
Wong and Minson, 2006).  Important questions remain as to what substances may be involved in 
cutaneous active vasodilation either as a direct vasodilator or by increasing NO production, and 
there are likely to be several redundant vasodilator pathways involved in mediating this response. 
 Adenosine Receptors 
The vasoactive effects of the purinergic receptors have been widely studied for several 
years. First recognized by Burnstock in 1978, these receptors were classified into two main 
groups: the P1 receptors, activated by adenosine; and the P2 receptors, activated by ATP. Several 
subtypes of receptors have subsequently been identified. Of these, both the A1 and A2 subtypes 
of adenosine receptors have been located in human skin (Stojanov and Proctor, 1989) and may 
exert vasoactive effects on the cutaneous circulation.  
Activation of A1/A2 adenosine receptors has been shown to mediate vasodilation in 
multiple organ systems including the skin (Abebe et al, 1995; Ngai and Winn, 1993; Stojanov 
and Proctor, 1989). As further evidence of a vasodilatory role for A1/A2 adenosine receptor 
activation in the cutaneous circulation, microdialysis infusion of 2.8 mM adenosine into the 
interstitial space of human skin has shown to elicit vasodilation to an extent similar to that 
achieved during whole body heating (Shibaski et al. 2007).  This vasodilation elicited by A1 and 
A2 adenosine receptors could occur through a variety of mechanisms by which adenosine 
receptors are known to mediate their effects.  
Activation of A1/A2 adenosine receptors may contribute to the skin blood flow responses 
to local skin and/ or whole body heating directly or by contributing to the production of NO.  For 
example, adenosine receptors have been found to be coupled to ATP-sensitive potassium 
channels (K+ATP) and have been found to induce NO and vasodilation through their actions on 
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these channels (Bryan & Marshall, 1999 a,b; Hein & Kuo, 1999). Additionally, adenosine-
induced vasodilation and NO production may stem from an increase in prostaglandin formation. 
Recent data from Mortensen et al. (2009), for example, has shown adenosine contributes to 
exercise hyperemia in the human leg primarily by increasing prostaglandin and NO formation. 
There is further evidence to suggest an interaction between histamine receptors and 
purinergic (A1/A2) receptors (Dickenson and Hill, 1994; Forsythe and Ennis, 1999) and between 
NK1 receptors and purinergic receptors (Burnstock, 2009; Ralevic, 2009).  Wong and colleagues 
(2006) have demonstrated that H1 histamine receptor activation contributes to cutaneous active 
vasodilation while Wong & Minson have shown NK1 receptor activation contributes to 
cutaneous thermal hyperemia (2011) and cutaneous active vasodilation (2004). As such, it is 
possible the effects of adenosine and adenosine receptor activation during hyperthermia may be 
manifest through the H1 and NK1 receptor activation components; however, these potential 
interactions await further investigation.  
 Potential Role for Adenosine Receptors in Cutaneous Thermal Hyperemia 
The cutaneous thermal hyperemic response to nonpainful local heating of the skin has 
been shown to be mediated by two independent mechanisms. The initial peak and nadir of this 
response is predominantly due to an axon reflex with a some contribution of NO, while the 
secondary plateau phase of this response is predominantly (~70%) mediated by NO (Minson et 
al. 2001). Important questions remain as to what substances may be involved in this response, 
either as a direct vasodilator or by increasing NO production. The study presented in Chapter IV 
was designed to investigate a possible A1/A2 adenosine receptor-mediated component to the 
cutaneous thermal hyperemic response. In addition, this study sought to determine whether a 
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portion of the NO-dependent component of this response may be explained by A1/A2 adenosine 
receptor activation.  
 Potential Role for Adenosine Receptors in Cutaneous Active Vasodilation 
As discussed earlier in this literature review, a co-transmission theory has been proposed 
to explain the mechanisms mediating cutaneous active vasodilation and the sweat response. By 
this theory, acetylcholine is co-released with other substances from sympathetic cholinergic 
nerves. The co-transmitters involved in mediating cutaneous vasodilation in response to whole 
body heating remain unknown; however, nitric oxide is known to directly mediate approximately 
45% of this response (Kellogg et al. 1995; Shastry et al. 1998). As such, important questions 
remain as to what substances may be involved in cutaneous active vasodilation either as a direct 
vasodilator or by increasing NO production. The study presented in Chapter V of this thesis was 
designed to investigate a role for adenosine receptor activation in contributing to cutaneous 
active vasodilation directly or through the production of NO. 
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Chapter 3 - Overview of Methodologies 
 Ethical Approval 
The Institutional Review Board of Kansas State University approved the protocols of 
both studies presented in this thesis. Subjects were recruited from the Kansas State University 
student population. Written, informed consent was obtained from each subject prior to 
participation and all protocols conformed to guidelines as set forth by the Declaration of 
Helsinki. 
 Subjects 
Thirteen subjects, including 10 men and 3 women between the ages of 20 and 28 
participated in the studies described in this thesis. A general health screening was given prior to 
participation in these studies to ensure that all subjects were healthy, nonsmokers, without 
diabetes or a history of cardiovascular disease. Subjects were not taking medications aside from 
oral contraceptives. All subjects were asked to refrain from caffeine, alcohol, and exercise for 12 
hours prior to each study.  
 Subject Monitoring 
Subjects were equipped with an electrocardiogram. Blood pressure was monitored beat-
by-beat via photoplethysmography (NexfinHD; BMEYE, Amsterdam, The Netherlands), and 
verified via automated brachial auscultation (S/5 Light Monitor; Datex-Ohmeda, GE Healthcare; 
Madison, WI, USA) every 10 minutes. Skin blood flow measurements were made from the 
lateral aspect of the left forearm and subjects rested supine with the experimental arm at heart 
level for the entire protocol. All experiments were performed in a thermoneutral laboratory.  
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During the experiments which consisted of a period of local heating, local skin 
temperature was controlled by local skin heating devices (PF5020 local heating units and 
PeriFlux 5020 Temperature Unit; Perimed; Jarfalla, Sweden). The local heating units used in 
these experiments cover a 10mm area of the skin surface, and allowed for temperature increases 
of 0.1°C increments. 
During the protocols which included a period of whole body heating, oral temperature 
was measured with a thermistor placed in the sublingual sulcus, and was used as an index of core 
body temperature. Oral temperature has previously been established as an accurate index of core 
temperature (Cranston, 1954; Mairiaux, 1983). Subjects’ oral temperature was monitored for  
5-10 minutes prior to, and for the duration of, the whole body heating period. 
 Subject Instrumentation 
 Microdialysis Technique 
All subjects had four microdialysis fibers, which are small tubes containing a semi-
permeable membrane, placed into the dermal layer of the skin of the left ventral forearm. The 
semi-permeable membrane in each fiber, as seen in figure 3-1(below), allows for the diffusion of 
compounds from an area of high concentration to an area of low concentration, resulting in the 
exchange of substances into and out of the probe from the extracellular fluid in the local area.  In 
the experiments described in this thesis, microdialysis fibers were used to administer drugs to 
local areas of the skin on the forearm. The membranes of the microdialysis fibers were 10 mm in 
length with a 55-kDa molecular mass cutoff (CMA 31 Linear Probe; CMA Microdialysis, 
Sweden). 
Fibers were placed approximately 3-5 cm apart on the ventral surface of the left forearm 
in the absence of anesthetics; however, ice was used to numb the skin prior to placement 
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(Hodges et al. 2009). Fiber placement was accomplished by first threading a 23-gauge needle 
through the skin at each desired site of microdialysis placement. A fiber was threaded through 
the lumen of the needle, and the needle was removed, leaving the membrane in place. 
Approximately 45-90 minutes were allowed for resolution of the trauma response induced by 
microdialysis fiber placement in the skin before the start of the protocol. During this time, all 
fibers were perfused with lactated Ringer’s solution at a rate of 4 μl/min.     
 Laser-Doppler Flowmetry 
Skin blood flow was recorded as red blood cell (RBC) flux and measured by laser-
Doppler flowmetry. Utilizing the Doppler shift of a laser as it is reflected off of red blood cells 
moving through the skin, this method of measurement provides a signal that is proportional to 
the speed and concentration red blood cells moving past the laser. Laser-Doppler flowmetry has 
been shown to be a reliable method of determining skin blood flow without influence from blood 
flow to the underlying muscle, and is widely used as a non-invasive method of obtaining a 
continuous index of skin blood flow. (Johnson et al, 1984; Saumet et al, 1988). 
Each site on a subject’s arm where a microdialysis probe was placed served as a separate 
recording site to examine the vasodilator response to local or whole body heating.  A laser 
Doppler probe (PeriFlux 5010 laser-Doppler perfusion monitor; Perimed; Jarfalla, Sweden), was 
placed on the forearm at each microdialysis site, directly over the placement of each semi-
permeable membrane. Local heating units (PF5020 local heating units and PeriFlux 5020 
Temperature Unit; Perimed; Jarfalla, Sweden) were placed on the skin directly over each 
microdialysis membrane, and an integrated laser-Doppler probe (Probe 413; Perimed; Jarfalla, 
Sweden) was placed in the center of each local heating unit to measure RBC flux directly over 
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each microdialysis site. Figure 3-1, below, illustrates the placement of a microdialysis fiber and 
laser-Doppler flow probe. 
 
 
Figure 3-1: Schematic drawing of the microdialysis technique and placement of a laser-Doppler flow probe. 
 
 Protocols 
 Local Heating 
Pre-infusion baseline skin blood flow measurements were recorded during a 5 minute 
period, with local heaters set at 33°C. Following baseline measurements, drug infusion through 
each microdialysis fiber was initiated. Following 45 minutes of drug infusion, the temperature 
of the local heaters was increased to 42°C at a rate of 1°C/10s (equivalent to 0.5°C/5 s; Minson 
et al. 2001; Wong et al. 2006). The temperature of the local heating units was maintained at 
42°C until a plateau in skin blood flow was observed and maintained for 20-30 min. 
 Whole Body Heating 
The protocol for the study described in Chapter V involves a period of whole body 
heating. Subjects were outfitted in a water-perfused suit covering the entire body except for the 
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head, hands, feet, and the left forearm from which skin blood flow measurements were recorded. 
Thermoneutral conditions were maintained during the microdialysis trauma resolution period and 
baseline data collection period, by circulating thermoneutral water at approximately 33°C 
through the suit. During periods of whole body heating for the purpose of testing the cutaneous 
vasodilator response to heat stress, water at a temperature of approximately 50°C from a second 
water tank was circulated through the suit to raise Tor at least 0.8°C above baseline. When a 
0.8°C rise in Tor had been achieved, subject’s temperature was maintained at this level to acquire 
a stable 10 min plateau of skin blood flow. Once a stable 10 min period of skin blood flow was 
achieved, subjects were cooled by perfusing 33°C water through the suit and removing the 
plastic rain suit. 
 Drugs Administered 
 Nitric Oxide Synthase Inhibition 
A 10mM dose of the L-arginine analog NG-nitro-L-arginine methyl ester (L-NAME; 
EMD Biosciences; San Diego, CA, USA), dissolved in lactated Ringer’s solution was used to 
inhibit NO synthase. This concentration of L-NAME has been previously shown to adequately 
inhibit NO synthase in human skin (Fieger and Wong, 2010; McCord et al. 2006; Minson et al. 
2001; Wilkins et al. 2003; Wong and Minson, 2006; Wong et al. 2004). L-NAME was 
administered via microdialysis at a rate of 4 μl/min for 45 minutes prior to the beginning of the 
local and whole body heating protocols.  
 A1/A2 Adenosine Receptor Inhibition 
A 4mM dose of theophylline (Tocris Biosciences; Ellisville, MO) dissolved in lactated 
Ringer’s solution was used as a competitive and non-selective A1/A2 adenosine-receptor 
antagonist.  Pilot data from our laboratory demonstrated that 4mM theophylline was the highest 
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dose that could attenuate the local heating response without eliciting vasodilation (Fieger and 
Wong, 2010). Theophylline was administered via microdialysis at a rate of 4 μl/min for 45 
minutes prior to the beginning of the local and whole body heating protocols. 
 Nitric Oxide Donor 
A maximal skin blood flow response was elicited at the end of every protocol via 
infusion of 28 mM sodium nitroprusside (SNP). This concentration of SNP has been previously 
shown to elicit maximal vasodilation in human skin (Kellogg, 1999; Minson, 2001). 
 Data Collection and Analysis 
Data were digitized and stored at 100 Hz on a personal computer. Data were analyzed 
offline using signal-processing software (Windaq; Dataq Instruments, Akron, OH, USA). 
Because of the transient and rapid nature of the initial peak and nadir responses (Chapter IV), a 
stable 30-90 second period of skin blood flow was used for analysis. For all other skin blood 
flow values reported in Chapters IV and V, a stable 3-5 minute period of skin blood flow was 
used for analysis. Skin blood flow data were converted to cutaneous vascular conductance 
(CVC), calculated as the ratio of skin blood flow to mean arterial pressure (RBC flux/mean 
arterial pressure). CVC data were expressed as a percentage of maximal vasodilation (%CVCmax) 
via SNP infusion and local heating to 43°C. 
Phase of menstrual cycle or oral contraceptive use was noted for female subjects but not 
controlled for in these experiments. Due to the robust nature of the skin blood flow response, 
phase of menstrual cycle did not significantly alter the overall responses when data from all 
subjects was averaged. Further, due to the lower number of female subjects who participated in 
the studies presented in Chapter IV (n=2) and Chapter V (n=1), it was not possible to run a full 
statistical analysis on the data from female subjects alone.  
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The statistical analyses performed included the use of paired t-tests, one way ANOVA 
with repeated measures and two way ANOVA with repeated measures. For all ANOVAs, 
Student-Newman-Keuls post hoc analysis was used to determine where significance differences 
occurred. All statistical analyses were performed using SigmaStat 3.5 (Systat Software; Point 
Richmond, CA, USA). All values are presented as mean ± SEM, and P-values < 0.05 were 
considered to be significant. 
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Chapter 4 - Adenosine Receptor Inhibition With Theophylline 
Attenuates the Skin Blood Flow Response To  
Local Heating In Humans 1
 Introduction 
 
Assessment of the thermal hyperemic response to local heating of the skin provides a 
convenient method of examining microvascular and endothelial function. The skin blood flow 
response to local heat application is commonly used to evaluate the vessels in various 
populations and disease states (Arora et al. 1998; Boignard et al. 2005; Stewart et al. 2004); 
however, the mechanisms underlying this heat-evoked cutaneous vasodilation are not 
completely understood. It is, therefore, important to investigate the mechanisms by which this 
response is mediated. 
Rapid, nonpainful, local heating of human skin elicits a thermal hyperemic response that 
is biphasic and characterized by a rapid rise in skin blood flow to an initial peak, followed by a 
brief nadir, and, finally, a more slowly established and prolonged plateau (Kellogg et al. 1999; 
Minson et al. 2001). It has been suggested the initial peak and nadir of cutaneous thermal 
hyperemia is primarily mediated by an axon reflex via activation of C-fiber afferent neurons 
(Magerl and Treede, 1996; Minson et al. 2001). The sensory neurons may elicit vasodilation 
through the release of substance P and/or calcitonin gene-related peptide, although these 
theories have yet to be directly tested experimentally. Additionally, nitric oxide (NO) has been 
shown to contribute modestly to the initial peak of the local heating response (Kellogg et al., 
                                                 
1 Reprinted with permission from “Adenosine receptor inhibition with theophylline 
attenuates the skin blood flow response to local heating in humans”. Exp Physiol 95: 946-
954, 2010. 
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1999; Minson et al. 2001). 
The secondary plateau phase of the local heating response, by contrast, consists of a 
sustained increase in skin blood flow and is ~70% dependent on NO, where inhibition of NO 
synthase (NOS) greatly attenuates the plateau phase of thermal hyperemia (Kellogg et al., 
1999; Minson et al. 2001). Kellogg and colleagues (2009) have recently provided evidence to 
suggest endothelial NOS (eNOS) may be the NOS isoform responsible for the NO-dependent 
secondary plateau; however, Stewart and colleagues (2007) have provided evidence that 
neuronal NOS (nNOS) is the isoform responsible for the increase in NO during local heating of 
the skin. Thus, it remains unclear as to the source of NO or what may stimulate the 
increase in eNOS and/or nNOS activity. Further, the oxidative state of the system and the 
rate of NO metabolism influence the amount of bioavailable NO such that increases in NO 
production may not translate to increased NO-dependent vasodilation. 
Several putative vasodilator pathways have been shown to induce smooth muscle 
relaxation, in part, through the production of NO. For example, H1 histamine receptor activation 
and prostaglandins, by activation of the cyclooxygenase-1 and -2 (COX- 1 and -2) pathways, 
have both been shown to elicit vasodilation in part through a NO-dependent component 
(Brown and Roberts, 2001; Salvemini, 1997). The contribution of H1 activation and the COX- 
1/COX-2 pathways to cutaneous thermal hyperemia has recently been investigated in 
independent studies (McCord et al. 2006; Wong et al. 2006). Inasmuch as these studies have 
demonstrated a minimal role for H1 activation (Wong et al. 2006) and no role for COX-1/COX-2 
activation (McCord et al. 2006) to cutaneous thermal hyperemia, it appears these pathways 
are not sources of NO during local heating. Although there are likely to be several redundant 
vasodilator pathways involved in mediating cutaneous thermal hyperemia, important questions 
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remain as to what substances may be involved in this response, either as a direct vasodilator or 
by increasing NO production. 
Activation of adenosine receptors has been shown to mediate vasodilation in the heart, 
brain, and several other organ systems of both animals and humans, including human skin 
(Abebe et al. 1995; Ngai and Winn, 1993; Olsson and Pearson, 1990; Stojanov and Proctor, 
1989). Further evidence suggests adenosine receptors may induce vasodilation, at least in part, 
by increasing NO production, and the presence of A1 and A2 adenosine receptors in human skin 
microcirculation has been established (Stojanov and Proctor, 1989). In view of these findings, it 
is reasonable to suggest adenosine-receptor activation may directly contribute to cutaneous 
thermal hyperemia as well as through an increase in NO production. 
The purpose of this study was to investigate a possible adenosine receptor-mediated 
component to the cutaneous thermal hyperemic response and to determine whether a portion of 
the NO-dependent component of this response may be explained by adenosine receptor 
activation. We hypothesized adenosine receptor blockade would result in an attenuated plateau 
response to local heat application. We further hypothesized simultaneous blockade of 
adenosine receptors combined with NOS inhibition would result in a greater attenuation of the 
NO-dependent secondary plateau compared to either NOS inhibition or adenosine receptor 
blockade alone. 
 Methods 
 Ethical Approval 
The Institutional Review Board of Kansas State University approved this study and 
subjects were recruited from the Kansas State University student population. Written, informed 
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consent was obtained from each subject prior to participation and all protocols conformed to 
guidelines as set forth by the Declaration of Helsinki. 
 Subjects  
Six subjects (4 men, 2 women) between the ages of 20 and 26 participated in the study. 
Power analysis of preliminary data indicated that 7-8 subjects would be required to reach 
significance. Initial power analysis was performed using mean and standard deviation for 6 mM 
and 8 mM theophylline. These higher concentrations resulted in greater variability and, as such, 
power analysis indicated more subjects would be required to reach significance. A 4 mM 
concentration of theophylline resulted in less variability and significance was achieved using six 
subjects. All subjects were healthy, nonsmokers, free of cardiovascular disease and diabetes, and 
were not taking any medications aside from oral contraceptives. All subjects were asked to 
refrain from caffeine, alcohol, and exercise for 12 hours prior to the study. Phase of menstrual 
cycle or oral contraceptive use was noted for female subjects but not controlled for in these 
experiments. Due to the robust nature of the thermal hyperemic response, phase of menstrual 
cycle did not significantly alter the overall responses when data from all subjects was averaged 
(see Data Analysis below). 
 Instrumentation and Measurements 
Skin blood flow measurements were made from the lateral aspect of the left forearm and 
subjects rested supine with the experimental arm at heart level for the entire protocol. Blood 
pressure was monitored beat-by-beat via photoplethysmography (NexfinHD; BMEYE, 
Amsterdam, The Netherlands), and verified via automated brachial auscultation (S/5 Light 
Monitor; Datex-Ohmeda, GE Healthcare; Madison, WI, USA) every 10 minutes. Four 
microdialysis fibers were placed into the dermal layer of the skin of the left ventral forearm. 
33 
Fibers were placed in the absence of anesthetics; however, ice was used to numb the skin prior to 
placement (Hodges et al. 2009). Fibers were placed approximately 3-5 cm apart. Fiber placement 
was accomplished by first threading a 23-gauge needle through the skin at each desired site of 
microdialysis placement. A fiber was threaded through the lumen of the needle, and the needle 
was removed, leaving the membrane in place. The membranes of the microdialysis fibers were 
10 mm in length with a 55-kDa molecular mass cutoff (CMA 31 Linear Probe; CMA 
Microdialysis, Sweden). Approximately 1.5-2 hours were allowed for resolution of the trauma 
response induced by microdialysis fiber placement in the skin before the start of the protocol. 
During this time, all fibers were perfused with lactated Ringer’s solution at a rate of 4 μl/min. 
Skin blood flow was recorded as red blood cell (RBC) flux, measured by laser-Doppler 
flowmetry (PeriFlux 5010 laser-Doppler perfusion monitor; Perimed; Jarfalla, Sweden). Local 
heating units (PF5020 local heating units and PeriFlux 5020 Temperature Unit; Perimed; 
Jarfalla, Sweden) were placed on the skin directly over each microdialysis membrane, and an 
integrated laser-Doppler probe (Probe 413; Perimed; Jarfalla, Sweden) was placed in the center 
of each local heating unit to measure RBC flux directly over each microdialysis site. 
 Experimental Protocol 
Data collection began when skin blood flow was observed to stabilize over the 
areas of microdialysis insertion via laser Doppler flowmetry, indicating resolution of the trauma 
response. Pre-infusion baseline skin blood flow measurements were recorded during a 5 minute 
period, with local heaters set at 33°C. Following baseline measurements, drug infusion through 
each microdialysis fiber was initiated. Each microdialysis fiber was randomly assigned one of 
four treatments: 1) lactated Ringer’s to serve as a control; 2) 4mM theophylline (Tocris 
Biosciences; Ellisville, MO, USA), a non-selective, competitive A1/A2 adenosine receptor 
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antagonist; 3) 10mM of the L-arginine analog NG-nitro-L-arginine methyl ester (L-NAME; 
EMD Biosciences; San Diego, CA, USA) to inhibit NOS; and 4) combined 4 mM theophylline 
and 10 mM-L-NAME, to simultaneously block adenosine-receptors and NOS, and to determine a 
potential interaction between adenosine receptors and NO. The concentration of theophylline 
was chosen based on extensive pilot work, which indicated 4 mM was the highest dose that 
could attenuate the local heating response without eliciting vasodilation. A 10 mM 
concentration of L-NAME has been shown previously to adequately inhibit NOS in human skin 
(Minson et al. 2001; McCord et al. 2006; Wong et al. 2006). All treatments were perfused at a 
constant rate of 4μl/min with a microinfusion pump (Bee Hive controller and Baby Bee Syringe 
Pumps; Bioanalytical Systems, West Lafayette, IN, USA). Pre-infusion baseline was taken as 
the last minute prior to drug infusion. Post-infusion baseline was taken as the last 1-2 minutes 
of infusion prior to local heating. 
All drugs were infused for at least 45 minutes prior to commencement of the local 
heating protocol. Extensive pilot work indicated that at least 45 minutes of infusion of 
theophylline was required for maximal effect and previous studies have demonstrated this 
duration of infusion adequately inhibits NOS (Holowatz, et al. 2005; Minson et al. 2001; 
McCord et al. 2006; Wong et al. 2006). Following 45 minutes of drug infusion, the temperature 
of the local heaters was increased to 42°C at a rate of 1°C/10s (equivalent to 0.5°C/5 s; Minson 
et al. 2001; Wong et al. 2006). The temperature of the local heating units was maintained at 
42°C until a plateau in skin blood flow was observed and maintained for 20-30 min. Once this 
stable plateau was established, a maximal skin blood flow response was elicited via infusion of 
sodium nitroprusside (SNP) at a rate of 4 μl/min and a simultaneous temperature increase to 
43°C. This temperature increase and dose of SNP have been previously determined effective 
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in eliciting a maximal skin blood flow response (Holowatz, et al. 2005; Minson et al. 2001; 
McCord et al. 2006; Wong et al. 2006). 
 Data Collection and Analysis.  
Data were digitized and stored at 100 Hz on a personal computer. Data were analyzed 
offline using signal-processing software (Windaq; Dataq Instruments, Akron, OH, USA). Skin 
blood flow data were converted to cutaneous vascular conductance (CVC), calculated as the ratio 
of skin blood flow to mean arterial pressure (RBC flux/mean arterial pressure). CVC data were 
expressed as a percentage of maximal vasodilation (%CVCmax) via SNP infusion and local 
heating to 43°C.  
Because of the transient and rapid nature of the initial peak and nadir responses, a 
stable 30-90 second period of skin blood flow was used for analysis. For the secondary plateau 
and maximal skin blood flow responses, a stable 3-5 minute period of skin blood flow was used 
for analysis. Due to the low number of female subjects who participated in this study (n = 2), a 
full statistical analysis could not be run to compare data from men and women. Any potential 
differences due to phase of menstrual cycle or oral contraceptive use would not be expected to 
significantly alter the data due to a low number of female subjects who participated in this study. 
Therefore, data from all subjects were averaged for statistical analysis. For each experimental 
site, a paired t-test was used to compare pre-drug infusion and post-drug infusion (before 
heating) baseline values.  
The percent contribution of A1/A2 receptor activation, NO, and combined A1/A2 receptor 
activation + NO were calculated as: 
[(%CVC max control – %CVC max treatment site) ÷ %CVCmax control)*100] 
where “treatment site” is theophylline, L-NAME, or combined theophylline + L-NAME. The 
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percent contribution for each treatment site was calculated for the initial peak and secondary 
plateau phases of local heating. A one way repeated measures ANOVA was used to compare the 
effect of drug treatment between experimental sites. The relative contribution of adenosine-
receptor activation and NO as well as the interaction between adenosine-receptor activation and 
NO was determined with the use of a one-way ANOVA with repeated measures. Percent 
contribution for each treatment site was compared using a one-way ANOVA with repeated 
measures. Maximal CVC values for each site were compared using a one-way ANOVA. For all 
ANOVAs, Student-Newman-Keuls post hoc analysis was used to determine where significance 
differences occurred. All statistical analyses were performed using SigmaStat 3.5 (Systat 
Software; Point Richmond, CA, USA). P-values <0.05 were considered to be significant and all 
data presented are mean ± SEM. 
 Results 
The administration of theophylline, L-NAME, or theophylline + L-NAME did not alter 
baseline skin blood flow values (p=0.210). That is, there was no significant difference between  
pre-infusion and post-infusion (before heating) baseline values within any of the treatment sites. 
There was no significant difference in baseline values between treatment sites (figure 4-1). 
Maximal absolute CVC responses did not differ between treatment sites (Table 4-1). The group 
mean data for the initial peak response in the four treatment sites is shown in figure 4-2. 
Compared to control (81 ± 2%CVCmax), the initial peak was significantly reduced in 
theophylline (68 ±2%CVCmax, p<0.01), L-NAME (54 ± 5%CVCmax, p<0.001), and 
theophylline + L-NAME (52 ± 5CVCmax, p<0.001) sites. The magnitude of reduction of the 
initial peak was significantly  
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greater in L-NAME and theophylline + L-NAME sites compared to theophylline only (p<0.01 
for all conditions). There was no significant difference between L-NAME and theophylline + L-
NAME. 
 
Table 4-1: Absolute Maximal CVC Values.  
 
 
 
Figure 4-1: Effect of drug treatment on baseline CVC. Baseline CVC values were not different between treatment sites. Pre-
drug infusion CVC was not significantly different compared to post-drug infusion CVC (not shown). Theo, theophylline 
(adenosine receptor antagonist); LNAME, NOS inhibition. 
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Figure 4-2: Effect of drug treatment on the initial peak response to local heating. The initial peak was significantly reduced 
in Theo, L-NAME, and Theo + L-NAME sites compared to control. L-NAME and Theo + L-NAME sites were significantly 
attenuated compared to Theo but were not significantly different from each other. Drug treatment notation same as in figure 4-1.  
*,p < 0.05 vs. control; # p < 0.05 vs. Theo. 
 
 
The nadir in control sites averaged 58 ± 4%CVCmax. The nadir was reduced in the 
LNAME (36 ± 4%CVCmax) and theophylline + L-NAME sites (32 ± 1%CVCmax) compared to 
control (p<0.01 for both sites); however, no significant reduction in the nadir was observed in 
the theophylline only site (52 ± 6%CVCmax) compared to control. L-NAME significantly 
reduced the nadir compared to theophylline (p<0.05). Theophylline + L-NAME significantly 
reduced the nadir compared to theophylline only (p<0.05) but not compared to L-NAME. Group 
mean data for the nadir in all four treatment sites is depicted in figure 4-3. 
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Figure 4-3: Effect of theophylline and L-NAME on the nadir response to local heating. Compared to control, Theo had no 
effect on the nadir. L-NAME and Theo + L-NAME significantly reduced the nadir compared to control and Theo but were not 
significantly different from each other. Drug treatment notation same as in figure 4-1. * p <0.05 vs. control; # p < 0.05 vs. Theo. 
 
 
The secondary plateau averaged 94 ± 2%CVCmax in control. Compared to control, the 
secondary plateau was reduced in theophylline (77 ± 2%CVCmax), L-NAME (60 ± 
2%CVCmax), and theophylline + L-NAME sites (53 ± 1%CVCmax, p<0.001 for all conditions). 
Compared to theophylline, the secondary plateau was reduced in L-NAME sites (p<0.001). The 
co-infusion of L-NAME + theophylline further reduced the secondary plateau compared to 
theophylline (p<0.001) and compared to L-NAME (p<0.05). These data are shown in figure 4-4. 
Data showing the percent contribution of A1/A2 receptor activation, NO, and combined A1/A2 
receptor activation + NO are shown in figure 4-5A (initial peak) and figure 4-5B (secondary 
plateau). The contribution of A1/A2 receptor activation to the initial peak was 16 ± 1%CVCmax, 
NO contributed 33 ± 1%CVCmax, and combined A1/A2 receptor activation + NO contributed 36 
± 2%CVCmax to the initial peak (figure 4-5A). 
 The contribution of combined A1/A2 receptor activation + NO and NO alone was 
significantly greater than the contribution of A1/A2 receptor activation alone (p < 0.001 for both 
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conditions); however, there was no significant difference between the contribution of combined 
A1/A2 receptor activation + NO and NO alone. For the secondary plateau phase (figure 4-5B), 
the percent contribution of A1/A2 receptor activation (18 ± 1%CVCmax) was significantly less 
than the contribution of NO alone (36 ± 1%CVCmax) and combined A1/A2 receptor activation + 
NO (44 ± 1%CVCmax; p < 0.001 for both conditions). Further, the contribution from NO alone 
was significantly less than the contribution of combined A1/A2 receptor activation + NO (p < 
0.001). 
 
Figure 4-4: Effect of theophylline and and L-NAME on the plateau phase to local heating. The plateau phase was 
significantly attenuated in all treatment sites compared to control. L-NAME and Theo + L-NAME attenuated the plateau phase 
compared to control and Theo. Theo + L-NAME further reduced the plateau phase compared to L-NAME. Drug treatment 
notation same as in figure 4-1. * p <0.05 vs. control; # P < 0.05 vs. Theo; ^ p < 0.05 vs. Theo + L-NAME. 
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Figure 4-5: Percent contribution of adenosine receptor activation, NO, and combined adenosine receptor activation + NO 
to the initial peak and secondary plateau. A: Percent contribution to the initial peak; B, Percent contribution to the secondary 
plateau. A1/A2 receptors, contribution of adenosine receptors (theophylline). * p < 0.05 vs. adenosine receptor activation; #, p < 
0.05 vs. NO. 
  
 
Table 4-2: Vasodilation to Increasing Doses of Theophylline. 
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 Discussion 
Two primary findings resulted from this study. First, adenosine receptor inhibition 
attenuated the initial peak and plateau of the local heating response, indicating adenosine 
receptor activation directly mediates a portion of the thermal hyperemic response. Second, 
combined inhibition of adenosine receptors and NOS further reduced the magnitude of the  
NO-dependent secondary plateau. Inasmuch as the combined effect of adenosine receptor 
inhibition and NOS inhibition further diminished, but did not abolish, the sustained thermal 
hyperemia, suggests adenosine receptor activation may account for a portion of the NO 
component of the local heating response, but is not the sole mechanism of NO production 
(Figures 4-4 and 4-5B). In addition, as demonstrated in Figures 4-5A and 4-5B, the percent 
contribution of A1/A2 receptor activation to both the initial peak and secondary plateau phases of 
cutaneous thermal hyperemia is relatively modest (16% and 18% contribution, respectively) 
whereas the NO contribution to both the initial peak and secondary plateau is substantially 
greater than the contribution of A1/A2 receptor activation. 
Adenosine receptor inhibition attenuated the thermal hyperemic response, which 
provides evidence of a direct role for adenosine receptors in mediating this response. The 
adenosine receptor-mediated component may be a result of direct action of these receptors on 
smooth muscle cells (Bryan and Marshall, 1999b; Baker and Sutton 1993; Skinner and Marshall, 
1996). Studies suggest adenosine-induced vasodilation may work through NO-independent 
mechanisms such as through its effects on adenylate cyclase, inositol phosphates, KATP 
channels, and/or changes in Ca2+ and K+ fluxes (Long et al. 1987; Bryan and Marshall 1999b; 
Marshall et al. 1993; Hein and Kuo, 1999). Clearly, more research is required to further elucidate 
these ideas as possible pathways involved in cutaneous thermal hyperemia. 
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In the present study, simultaneous inhibition of adenosine receptors and NOS diminished, 
but did not abolish, the local heating plateau. These data suggest adenosine receptor activation 
may be one source of NO yet the majority of NO produced during local heating of the skin is 
from sources other than adenosine receptor activation (figures 4-4 and 4-5B). Several in vivo and 
in vitro studies have suggested a close interaction between adenosine receptor activation and NO 
in a host of tissues and vascular beds (Li et al. 1998; Martin et al. 2006, Mortenson et al, 2009; 
Sobrevia et. al, 1997; Vials and Burnstock, 1993) and adenosine receptor activation could 
mediate NO production through a variety of mechanisms such as through alterations in Ca2+ flux 
and/or K+ATP channels (Bryan and Marshall, 1999 a,b; Hein and Kuo, 1999). 
It is also possible adenosine-induced vasodilation and NO production stems from an 
increase in prostaglandin formation. Recent data from Mortensen et al. (2009) has shown 
adenosine contributes to exercise hyperemia in the human leg primarily by increasing 
prostaglandin and NO formation. In the context of cutaneous thermal hyperemia in humans, 
McCord et al. (2006) found inhibition of the COX-1 and COX-2 pathways did not alter the skin 
blood flow response to direct local heating and combined inhibition of NOS and COX-1/COX-2 
had no further effect compared to NOS inhibition alone, suggesting the COX-1/COX-2 pathways 
are not involved in the thermal hyperemic response and COX-1/COX-2 are not a source of NO. 
Although the data from McCord et al. (2006) strongly suggest COX-1/COX-2 (prostaglandin 
production) are not involved in the cutaneous thermal hyperemic response, we cannot completely 
rule out that a portion of the adenosine receptor component observed in this study may be 
explained by activation of the COX pathway. 
The data from the present study further suggest a large portion of the NO component 
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cannot be explained by adenosine receptor activation. Several possibilities have been proposed to 
explain the large increase in NO production during local heating. It is possible application of heat 
to the skin may directly cause endothelial production of NO via a shear stress mechanism; 
however, reactive hyperemia, a condition which would presumably increase shear stress, appears 
to be independent of NO in human skin (Wong et al. 2003; Zhao et al. 2004). It is also possible 
the direct effect of heat directly enhances eNOS activity or increases the binding of heat shock 
protein 90 (HSP90) to eNOS thereby resulting in greater NO production. The direct effect of heat 
enhancing eNOS activity appears to be unlikely (Venturini et al. 1999) and inhibition of HSP90 
appears to account for a modest portion of the NO response (Shastry and Joyner, 2002). 
Multiple and redundant pathways are undoubtedly involved in this response and it is unlikely 
that any one pathway will completely account for the increase in NO production, yet experiments 
designed at investigating mechanisms underlying the large increase in NO production in 
response to local skin heating remain important areas of future research. 
 Experimental Considerations and Limitations 
While the data from the present study suggest involvement of adenosine receptors in the 
thermal hyperemic response to local heating, there are at least four limitations to be addressed. 
First, use of a competitive, but non-selective, adenosine-receptor antagonist, theophylline, does 
not allow for specific roles of adenosine receptor subtypes during local heating of skin to be 
distinguished. The existence of both A1 and A2 adenosine receptors has been demonstrated in 
human skin (Stojanov and Proctor, 1989). Activation of both A1 and A2 adenosine receptors have 
been shown to induce vasodilation (Bryan and Marshall, 1999b; Danialou et al. 1997; Sobrevia 
et al. 1997; Vials and Burnstock, 1993); however, the specific roles and contributions of each of 
these receptor subtypes appears to differ according to the type of tissue and conditions in which 
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they are studied. For example, Bryan and Marshall (1999 a, b) have demonstrated A1 receptors 
are primarily responsible for adenosine-mediated vasodilation in skeletal muscle under resting, 
hypoxic conditions whereas Ray and Marshall (2009) have shown A2A receptor activation 
induces vasodilation in skeletal muscle in response to tetanic contractions. Both A1 and A2 
isoforms of the adenosine receptor have been found in human skin and may display discrepant 
activation patterns similar to skeletal muscle. As such, we chose to use theophylline to 
antagonize both A1 and A2 receptor subtypes. 
Second, based on the experimental approach, we can only discuss the data in terms of 
an adenosine receptor activation component and not adenosine, per se, being involved in 
cutaneous thermal hyperemia. Although adenosine is the most likely candidate to bind to, and 
activate, A1/A2 receptors, the present data suggest an indirect role for adenosine, per se, and 
we cannot rule out the possibility that some other substance(s) bind to, and activate, A1/A2 
receptors. 
Third, a 4 mM dose of theophylline was the maximum dose that could be administered 
via microdialysis without causing non-specific vasodilation (Table 4-2). In preliminary 
experiments, concentrations higher than 4 mM resulted in substantial vasodilation. This 
nonspecific vasodilation of adenosine receptor antagonists is not unique to human skin. Casey et 
al. (2009; 2010) have demonstrated increases in forearm blood flow and vascular conductance 
under baseline conditions in response to infusion of a similar non-specific adenosine receptor 
antagonist, aminophylline. The increase in baseline skin blood flow observed with higher 
concentrations of theophylline is most likely due to the phosphodiesterase inhibitor properties of 
theophylline, which would act to increase cAMP levels and result in smooth muscle relaxation 
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(Taddei et al. 1991). It is possible our data underestimate the contribution of adenosine receptor 
activation to cutaneous thermal hyperemia; however, our data clearly indicate a direct role for 
adenosine receptor activation to cutaneous thermal hyperemia as well as a possible source of 
NO. 
Fourth, theophylline and aminophylline are the most common adenosine receptor 
antagonists used in human-based experiments. It is possible results may have been different 
if aminophylline was used instead of theophylline. This seems unlikely inasmuch as Radegran 
and Calbet (2001) and Mortensen et al. (2009) have observed significant reductions in leg blood 
flow during exercise using theophylline and Casey et al. (2009; 2010) have observed similar 
reductions in forearm blood flow during hypoxic exercise using aminophylline. Thus, it appears 
theophylline and aminophylline are similarly effective at antagonizing A1 and A2 adenosine 
receptors. 
 Summary and Conclusions 
While the data from this study indicate adenosine receptor activation may directly 
mediate a portion of the cutaneous vasodilation and may account for a portion of the NO 
component, there is still a substantial degree of vasodilation for which adenosine receptor 
activation cannot account. Mechanisms attending cutaneous thermal hyperemia are undoubtedly 
complex and redundant and, as such, inhibition or blockade of one or two potential vasodilator 
pathways is unlikely to completely abolish this robust vasodilation. As such, current and future 
research aimed at investigating potential mechanisms involved in cutaneous thermal hyperemia 
will have to be taken with the understanding that it is unlikely one or more vasodilator pathways 
are simply “additive” and the redundant nature of the system may unmask roles for other 
unexamined vasodilator pathways when one or two pathways are blocked. For example, although 
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McCord et al. (2006) observed no role for the COX pathway when COX was inhibited 
either independently or combined with inhibition of NOS, it is possible a role for the COX 
pathway may be unmasked when combined with adenosine receptor inhibition. 
In conclusion, this study provides evidence for the direct involvement of adenosine 
receptors in the cutaneous thermal hyperemic response to local heating as observed by the 
reduced initial peak and plateau phases of thermal hyperemia in theophylline sites. Inasmuch 
as combined inhibition of adenosine receptors and NOS unmasked a larger reduction in skin 
blood flow than either adenosine inhibition or NOS inhibition alone, these data suggest 
adenosine receptor activation can account for a portion of the NO component of thermal 
hyperemia but a large portion of the NO component is due to sources other than adenosine 
receptor activation. Moreover, although these data provide evidence of a direct role for 
adenosine receptor activation, this represents a relatively minor contribution compared to NO. 
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Chapter 5 - Does Adenosine Receptor Activation Contribute To 
Cutaneous Active Vasodilation in Humans? 
 Introduction 
In response to an increase in core body temperature, humans exhibit a substantial increase 
in skin blood flow and sweating. This cutaneous vasodilation and increase in sudomotor activity 
is the primary autonomic means by which humans defend against increasing core temperatures. 
As core temperature rises during heat stress, an initial rise in skin blood flow occurs via 
withdrawal of sympathetic adrenergic vasoconstriction. With a further increase in temperature to 
a specific core temperature threshold, reflex cutaneous active vasodilaton occurs, concurrent 
with the onset of sweating (Grant and Holling, 1938; Roddie et al. 1957). Active vasodilation 
accounts for 85-95% of the substantial increase in skin blood flow that occurs during heat 
exposure. 
 The active vasodilator system is known to be mediated by sympathetic cholinergic 
nerves and is responsible for both the sweat and skin blood flow responses. By the current co-
transmission theory, acetylcholine is released from sympathetic nerves along with one or more 
unknown neurotransmitters to mediate sweating and cutaneous vasodilation, respectively. 
Kellogg and colleagues (1995) demonstrated acetylcholine is primarily responsible for the sweat 
response, whereas cutaneous vasodilation is, therefore, mediated by the co-transmitter(s) 
released with acetylcholine. The responsible co-transmitter(s) remain unknown; however, several 
substances and vasodilator pathways have been shown to play a role in cutaneous active 
vasodilation, including vasoactive intestinal peptide (VIP) (Bennet et al, 2004; Wilkin et al, 
2005), H1 histamine receptor activation (Wong et al. 2004), neurokinin-1 (NK1) receptor 
activation (Wong and Minson, 2006), and vasoactive prostanoids (McCord et al. 2006). 
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Additionally, nitric oxide (NO) has been shown to directly mediate 30-45% of active 
vasodilation (Kellogg et al. 1998; Shastry et al. 1998; Wilkins et al. 2003). In contrast to the 
permissive role of NO in active vasodilation occurring in the rabbit ear (Farell and Bishop, 
1995),  multiple studies have provided evidence of a direct role for NO in active vasodilation in 
human skin (Kellogg et al. 2003; Wilkins et al. 2003). In the skin of the human forearm, Kellogg 
and colleagues (2003) measured increases in cutaneous interstitial concentrations of NO that 
occurred along with increases in skin blood flow following the onset of active vasodilation. 
Additionally, Wilkins et al. (2003) demonstrated that low-dose infusion of sodium nitroprusside, 
an exogenous source of NO, does not fully restore the skin blood flow response to whole body 
heating following NO synthase inhibition. Taken together, these data suggest an increase in NO 
production, rather than the presence of a basal level of NO, is required for full expression of 
cutaneous active vasodilation, and indicate NO is not permissive but directly mediates a portion 
of cutaneous active vasodilation.  Data from Wilkins et al. (2003) further suggest NO may act 
synergistically with another vasoactive substance during cutaneous active vasodilation, in 
addition to having a direct role as a vasodilator, 
While NO is known to directly mediate a significant component of the increase in skin 
blood flow during heat stress, it remains unclear as to the source of NO, what may cause the 
increase in NO synthase activity, or the NO synthase isoform involved in cutaneous active 
vasodilation. Kellogg and colleagues (2009) have recently addressed the question as to which 
NO synthase isoform may be involved in cutaneous active vasodilation.  The data from these 
investigators suggests neuronal NO synthase (nNOS) may be the NO synthase isoform 
responsible for mediating NO generation during cutaneous active vasodilation, as nNOS 
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inhibition, but not endothelial NO synthase inhibition, attenuates the skin blood flow response to 
whole body heat stress.  
Several possible sources may contribute to the increased NO generation by nNOS during 
active vasodilation. Shibaski et al (2002) found acetylcholine may contribute to NO synthesis; 
however, this contribution appears to be isolated to the early stages of heat stress, where 
acetylcholine may not be a significant source of NO once significant vasodilation has occurred. 
Additionally, while H1 histamine receptor activation and NK1 receptor activation have both been 
shown to directly mediate a portion of the cutaneous vasodilation during hyperthermia, evidence 
suggests these receptor types may also contribute to the NO component (Wong and Minson, 
2006; Wong et al. 2004).  Important questions remain as to what substances may be involved in 
cutaneous active vasodilation either as a direct vasodilator or by increasing NO production, and 
there are likely to be several redundant vasodilator pathways involved in mediating this response. 
Adenosine A1 and A2 receptors have been shown to be located in human skin 
microcirculation and activation of these receptors has been shown to mediate vasodilation in 
multiple organ systems including the skin (Stojanov and Proctor, 1989). Furthermore, 
microdialysis infusion of 2.8 mM adenosine into the interstitial space of human skin has shown 
to elicit vasodilation to an extent similar to that achieved during whole body heating (Shibaski et 
al. 2007) and adenosine receptors have been shown to induce vasodilation, at least in part, by 
increasing NO production (Mortensen et al. 2009; Stewart et al. 2004; Vials and Burnstock, 
1993). In the context of human skin, we have recently demonstrated adenosine receptor 
activation contributes to the rise in skin blood flow elicited by local heating of the skin both 
directly and through the production of NO (Fieger and Wong, 2010); however, to date, there 
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have been no studies investigating a potential role for adenosine and/or adenosine receptor 
activation to cutaneous active vasodilation. 
In view of these findings, the purpose of this study was to determine whether adenosine 
receptor activation contributes to reflex cutaneous active vasodilation and whether a portion of 
the NO component of cutaneous active vasodilation might be explained by A1/A2 adenosine 
receptor activation. We hypothesized a direct role for adenosine receptor activation would be 
suggested by an attenuation of the skin blood flow response to heat stress in the presence of the 
non-selective A1/A2 receptor antagonist theophylline. In addition, we hypothesized adenosine 
receptor inhibition combined with NO synthase inhibition would further attenuate this response, 
which would suggest adenosine receptor activation may also contribute to cutaneous active 
vasodilation through the production of NO. 
 Methods 
 Ethical Approval 
Subjects were recruited from the Kansas State University student population and written 
informed consent was obtained from each subject prior to participation. This study was approved 
by the Institutional Review Board of Kansas State University and conformed to the guidelines as 
set forth by the Declaration of Helsinki.   
 Subjects 
Seven subjects (6 men, 1 woman; ages 21-28) participated in this study. All subjects were 
healthy, nonsmokers, free of cardiovascular disease and diabetes, and were not taking any 
medications, including oral contraceptives. All subjects were asked to refrain from caffeine, 
alcohol, and exercise for 12 hours prior to the study.  
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 Instrumentation and Measurements 
All experiments were performed in a thermoneutral laboratory. Skin blood flow 
measurements were made from the lateral aspect of the left forearm and subjects rested supine 
with the experimental arm at heart level for the entire protocol. Blood pressure was monitored 
beat-by-beat via photoplethysmography (NexfinHD; BMEYE, Amsterdam, The Netherlands), 
and verified via automated brachial auscultation (S/5 Light Monitor; Datex-Ohmeda, GE 
Healthcare; Madison, WI, USA) every 10 minutes.  
Four microdialysis fibers were placed into the dermal layer of the skin of the left ventral 
forearm. Fibers were placed in the absence of anesthetics; however, ice was used to numb the 
skin prior to placement (Hodges et al. 2009). Fibers were placed approximately 3-5 cm apart. 
Fiber placement was accomplished by first threading a 23-gauge needle through the skin at each 
desired site of microdialysis placement. A fiber was threaded through the lumen of the needle, 
and the needle was removed, leaving the membrane in place. The membranes of the 
microdialysis fibers were 10 mm in length with a 55-kDa molecular mass cutoff (CMA 31 
Linear Probe; CMA Microdialysis, Sweden). Approximately 1.5-2 hours were allowed for 
resolution of the trauma response induced by microdialysis fiber placement in the skin before the 
start of the protocol. During trauma resolution, all fibers were perfused with lactated Ringer’s 
solution at a rate of 4 μl/min. Skin blood flow was recorded as red blood cell (RBC) flux, 
measured by laser-Doppler flowmetry (PeriFlux 5010 laser-Doppler perfusion monitor; Perimed; 
Jarfalla, Sweden). Local heating units (PF5020 local heating units and PeriFlux 5020 
Temperature Unit; Perimed; Jarfalla, Sweden) were placed on the skin directly over each 
microdialysis membrane, and an integrated laser-Doppler probe (Probe 413; Perimed; Jarfalla, 
Sweden) was placed in the center of each local heating unit to measure RBC flux directly over 
each microdialysis site. 
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Subjects wore a water-perfused suit (Allen Vanguard; Ottawa, ON, Canada) to control 
whole-body temperature, which covered the entire body except the head, hands, feet and 
experimental forearm.  Oral temperature was measured by placing a thermistor in the sublingual 
sulcus and used as an index of core temperature.  Subjects’ oral temperature was monitored for 
5-10 minutes prior to, and for the duration of, the whole body heating period. Thermoneutral 
water (33°C) was perfused through the suit during the trauma resolution period following 
microdialysis placement, and during the baseline data collection and drug infusion periods. 
During the whole-body heating period, subjects were covered with a water-impermeable rain suit 
to minimize evaporative heat loss, and hot water (50°C) was perfused through the suit to raise 
subjects’ oral temperature at least 0.8°C above baseline. 
 Experimental Protocol 
Following the trauma resolution period, baseline data were collected for 10 min with 
thermoneutral water pumped through the suit to maintain subjects’ core temperature. After 
baseline measurements, drug infusion through each microdialysis fiber was initiated, and each 
site was randomly assigned one of four treatments: 1) lactated Ringer’s to serve as a control; 2) 
4mM theophylline (Tocris Biosciences; Ellisville, MO, USA), a non-selective, competitive 
A1/A2 adenosine-receptor antagonist; 3) 10mM of the L-arginine analog NG-nitro-L-arginine 
methyl ester (L-NAME; EMD Biosciences; San Diego, CA, USA) to inhibit NOS; and 4) 
combined 4 mM theophylline and 10 mM-L-NAME, to simultaneously block adenosine-
receptors and NO synthase, and to determine a potential interaction between adenosine receptors 
and NO. Data from our laboratory demonstrated that 4 mM theophylline was the highest dose 
that could attenuate the local heating response without eliciting vasodilation (Fieger and Wong, 
2010). A 10 mM concentration of L-NAME has been shown previously to adequately inhibit NO 
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synthase in human skin (Fieger and Wong, 2010; McCord et al. 2006; Minson et al. 2001; 
Wilkins et al. 2003; Wong and Minson, 2006; Wong et al. 2004) . All treatments were perfused 
at a constant rate of 4μl/min with a microinfusion pump (Bee Hive controller and Baby Bee 
Syringe Pumps; Bioanalytical Systems, West Lafayette, IN, USA). Drug infusion began 45 
minutes prior to whole body heating and continued through the duration of the heating period. 
We previously demonstrated that at least 45 minutes of theophylline infusion was required for 
maximal effect on adenosine receptors (Fieger and Wong, 2010). Previous studies have also 
demonstrated this duration of L-NAME infusion adequately inhibits NO synthase (Fieger and 
Wong, 2010; McCord et al. 2006; Minson et al. 2001; Wilkins et al. 2003; Wong and Minson, 
2006; Wong et al. 2004). 
Following 45 minutes of drug infusion, 50°C water was circulated through the suit to 
begin the whole body heating period. The heating period raised subjects’ oral temperature at 
least 0.8°C and was 35-50 minutes in duration. When a 0.8°C rise in Tor had been achieved, 
subject’s temperature was maintained at this level to acquire a stable 10 min plateau of skin 
blood flow. Once a stable 10 min period of skin blood flow was achieved, subjects were cooled 
by perfusing 33°C water through the suit and removing the plastic rain suit. A maximal skin 
blood flow response was elicited via infusion of 28 mM sodium nitroprusside (SNP) at a rate of 
4 μl/min and a simultaneous temperature increase to 43°C at a rate of 1°C/10s (equivalent to 
0.5°C/5 s; (Fieger and Wong, 2010; Minson et al. 2001) This temperature increase and dose of 
SNP have been previously determined effective in eliciting a maximal skin blood flow response 
(Minson et al. 2001). 
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 Data Collection and Analysis 
Data were acquired, digitized, and stored at 100 Hz (Windaq; Dataq Instruments; Akron, 
OH, USA) on a personal computer. Data were analyzed offline using signal-processing software 
(Windaq). Skin blood flow data were converted to cutaneous vascular conductance (CVC), 
calculated as the ratio of skin blood flow to mean arterial pressure (RBC flux/mean arterial 
pressure).  The CVC data were expressed as a percentage of maximal vasodilation (%CVCmax) 
via SNP infusion and local heating to 43°C. A stable 5 min period of skin blood flow was used 
for analysis of baseline, whole body heating plateau, and maximal skin blood flow.  To 
determine the magnitude of increase in CVC for a given increase in oral temperature, skin blood 
flow during the final minute of each 0.1°C increase in oral temperature from baseline (∆Tor 
0.0°C) to the end of heat stress (∆Tor 0.8°C) was used for analysis. The percent contribution of 
A1/A2 receptor activation, NO, and combined A1/A2 receptor activation + NO were  
calculated as: 
[(%CVC max control – %CVC max treatment site) ÷%CVCmax control)*100] 
where “treatment site” is theophylline, L-NAME, or combined theophylline + L-NAME. 
Data from all subjects were averaged for statistical analysis as there was only one female 
subject who participated in this study. For each experimental site, a paired t-test was used to 
compare pre-drug infusion and post-drug infusion (before heating) baseline values. A one way 
repeated measures ANOVA was used to compare the effect of drug treatment (i.e., post-drug 
infusion baseline) between experimental sites.  The effect of drug treatment on the increase in 
CVC during hyperthermia was compared with the use of a one-way ANOVA with repeated 
measures. A two-way ANOVA with repeated measures was used to compare the effect of drug 
treatment on the increase in CVC for each 0.1°C rise in oral temperature (drug treatment x CVC 
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x ∆Tor).  Percent contribution for each treatment site was compared using a one-way ANOVA 
with repeated measures. Maximal CVC values for each site were compared using a one-way 
ANOVA. For all ANOVAs, Student-Newman-Keuls post hoc analysis was used to determine 
where significance differences occurred. All statistical analyses were performed using SigmaStat 
3.5 (Systat Software; Point Richmond, CA, USA). P-values < 0.05 were considered to be 
significant and all data presented are mean ± SEM.  
 Results 
The administration of theophylline, L-NAME, or theophylline + L-NAME did not alter 
baseline skin blood flow values. That is, there was no significant difference between pre-infusion 
and post-infusion (before heating) baseline values within any of the treatment sites (Table 5-1). 
Although there was a tendency for baseline CVC to be elevated in the theophylline sites, there 
was no significant difference in post-drug infusion baseline values between treatment sites 
(Figure 5-1). Maximal absolute CVC responses did not differ between treatment sites (Table 5-
2).  
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Figure 5-1: Effect of drug treatment on baseline skin blood flow.  Although there was a tendency for a higher baseline in 
theophylline sites, this did not reach significance versus all other treatment sites.  In all, post-drug infusion baseline was not 
significantly different between sites.  Theophylline, A1/A2 adenosine receptor inhibition; L-NAME, NO synthase inhibition. 
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Figure 5-2 depicts the effect of drug treatment on the CVC response to whole body heat 
stress with a 0.8°C increase in oral temperature.  In the control sites, CVC increased during 
whole body heating to 63 ± 4%CVCmax. CVC was significantly reduced in L-NAME sites (48 ±  
2%CVC max; p < 0.05) compared with control sites.  There was no effect of theophylline on the 
CVC response to heat stress (61 ± 5%CVC max) compared to the control sites; however, 
theophylline plus L-NAME sites were significantly reduced (39 ± 3%CVC max) compared to 
control sites (p < 0.001) and compared to L-NAME only sites (p < 0.05).  
 
 Pre-Infusion Post-Infusion P Value 
Control          14 ± 3           15 ± 3          0.4 
Theophylline          17 ± 6           22 ± 8          0.1 
L-NAME          15 ± 5           13 ± 3          0.5 
Theophylline + L-NAME 17 ± 4                       17 ± 2                      0.9 
Values are mean ± SEM. There was no significant difference between pre-drug 
infusion and post-drug infusion baseline values. Theophylline: A1/A2 adenosine 
receptor inhibition; L-NAME: NO synthase inhibition. 
 
Table 5-1: Pre- and Post- Drug Infusion Baseline Values. 
 
 Maximal CVC 
Control 2.11 ± 0.7 
Theophylline 2.16 ± 0.5 
L-NAME 1.9 ± 0.7 
Theophylline + L-NAME 2.5 ± 0.8 
Values are mean ± SEM. There was no significant difference in maximal 
CVC values between sites. 
 
Table 5-2: Absolute Maximal CVC Values. 
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Figure 5-2: Effect of A1/A2 adenosine receptor inhibition and NO synthase inhibition on the skin blood flow response to 
whole body heat stress.   Inhibition of A1/A2 receptors with theophylline (open bars) had no effect on cutaneous active 
vasodilation compared to control (black bars).  Inhibition of NO synthase (L-NAME; gray bars) and combined A1/A2 + NO 
synthase inhibition (theophylline + L-NAME; hatched bars) attenuated active vasodilation compared to both control and 
theophylline.  Values are mean ± SEM. *, p < 0.05 vs. control; #, p < 0.05 vs. L-NAME. 
 
Figure 5-3 (below) depicts the increase in CVC in each of the treatment sites as a 
function of increasing oral temperature (CVC vs. ∆Tor).  In control (thick solid lines; filled 
circles) and theophylline (thick dashed lines; open circles) sites, CVC began to increase with a 
0.2°C increase in oral temperature (*, p < 0.05 vs. baseline, ∆Tor = 0.0).  In contrast, CVC in L-
NAME (thin solid lines; filled squares) and L-NAME + theophylline (thin dashed lines; open 
squares) were not significantly different from baseline (∆Tor = 0.0) until a 0.4°C increase in oral 
temperature was achieved.  The L-NAME and L-NAME + theophylline sites were significantly 
attenuated compared to control and theophylline only sites at all increments of ∆Tor ≥ 0.2°C.  
Lastly, L-NAME + theophylline sites were significantly reduced at all increments of  ∆Tor ≥ 
0.5°C compared to L-NAME only sites.  
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Figure 5-3: Increase in CVC during whole body heating as a function of increasing oral temperature.  The rise in CVC 
during heat stress was plotted against increasing oral temperature in 0.1°C increments.  There was no difference between control 
and theophylline sites in terms of the magnitude of increase in CVC or in terms of the onset of vasodilation.  The magnitude of 
increase in CVC during hyperthermia was significantly attenuated in L-NAME and combined theophylline + L-NAME sites 
compared to both control and theophylline only sites.  Similarly, the onset for vasodilation L-NAME and combined L-NAME 
sites was shifted to a higher oral temperature compared to control and theophylline only sites.  Values at each 0.1°C increment in 
oral temperature are mean ± SEM.  *, p < 0.05 vs. baseline (i.e., ΔTor = 0.0°C); ‡, p < 0.05 vs. control and theophylline only sites; 
#, p < 0.05 vs. L-NAME only sites.   
 
The percent contribution of A1/A2 adenosine receptors, NO, and combined A1/A2 
adenosine receptors + NO to cutaneous active vasodilation is shown in Figure 5-4.  The percent 
direct contribution of A1/A2 receptor activation (1.0 ± 1%) was significantly less than the percent 
contribution of NO (32± 2%) and combined NO + A1/A2 receptor activation (53 ± 2%; p < 0.001 
for both conditions) to the plateau in CVC during hyperthermia.  In addition, the percent 
contribution of NO was significantly less than the percent contribution from combined NO + 
A1/A2 receptor activation (p < 0.001). 
* 
* *‡# 
 
* 
‡# 
‡# ‡# 
Control 
Theophylline 
L-NAME 
Theophylline + L-NAME 
 
60 
 
%
 C
on
tri
bu
tio
n 
to
 C
ut
an
eo
us
 A
ct
iv
e 
V
as
od
ila
tio
n
C
ut
an
eo
us
 V
as
cu
la
r C
on
du
ct
an
ce
0
10
20
30
40
50
60
70
%A1/A2 Receptors %Nitric Oxide %A1/A2 Receptors +
Nitric Oxide
*
*#
 
Figure 5-4: Percent contribution of A1/A2 receptor activation, NO, and combined A1/A2 receptor activation + NO to 
cutaneous active vasodilation.  A1/A2 adenosine receptor activation made little to no direct contribution to cutaneous active 
vasodilation.  The contribution of NO was ~30% while the combined contribution of A1/A2 adenosine receptor activation + NO 
was ~50%.  Values are mean ± SEM. *, p < 0.05 vs. %A1/A2 receptor activation; #, p < 0.05 vs. % Nitric oxide. 
 
 Discussion 
The aim of this study was to determine a potential role for A1/A2 adenosine receptor 
activation to reflex cutaneous active vasodilation. Specifically, this study was designed to test the 
hypotheses that 1) adenosine receptor activation directly contributes to cutaneous active 
vasodilation; and 2) adenosine receptor activation contributes to a portion of the known NO 
component of this response to heat stress. In contrast to our first hypothesis, we found adenosine 
receptor inhibition with theophylline did not attenuate the skin blood flow response to whole 
body heating, suggesting no direct contribution of adenosine receptor activation to reflex 
cutaneous active vasodilation.  A role for adenosine receptors became evident, however, when 
A1/A2 receptor inhibition was combined with NO synthase inhibition.  That is, inhibition of NO 
synthase with L-NAME appeared to unmask a role for adenosine receptor activation that was not 
observed when only adenosine receptors were blocked with theophylline, suggesting any direct 
contribution of adenosine receptor activation to cutaneous active vasodilation is modest, at best, 
61 
and masked by the vasodilator actions of NO and, presumably, other vasodilators (Figure 5-4).   
Inhibition of adenosine receptor activation did not alter the core temperature threshold for the 
onset of cutaneous active vasodilation compared to control sites (Figure 5-3).  Taken together, 
these data suggest there is no direct role for adenosine receptor activation contributing to either 
the onset or magnitude of cutaneous active vasodilation. 
In support of our second hypothesis, our data suggest adenosine receptor activation 
mediates a portion of the known NO component of cutaneous active vasodilation. This was 
evidenced by the further reduction in skin blood flow in sites treated with theophylline + L-
NAME compared to sites treated with L-NAME only (Figures 5-2, 5-3, and 5-4).  Inasmuch as 
the combined effect of L-NAME and theophylline was found to diminish but not abolish the skin 
blood flow response to heat stress, these data further suggest a substantial portion of the NO 
component cannot be explained by adenosine receptor activation.  In addition, the onset for 
cutaneous active vasodilation was shifted to a higher oral temperature in theophylline + L-
NAME sites (∆Tor 0.5°C) compared to control and theophylline sites (∆Tor 0.2°C) as well as 
compared to L-NAME only sites (∆Tor 0.4°C).  The observation that combined theophylline + L-
NAME shifted the onset of cutaneous active vasodilation to a higher oral temperature compared 
to L-NAME only sites suggests not only that adenosine receptor activation may mediate a 
portion of the increase in NO but also that adenosine receptor activation may be partially 
responsible for the increase in NO during the early stages of hyperthermia. 
The combined effects of theophylline and L-NAME in this study indicate adenosine 
receptors are activated during whole body heat stress to induce NO production and subsequent 
vasodilation, which is consistent with previous studies that have demonstrated A1/A2 receptors 
can induce vasodilation through the production of NO. By one proposed mechanism, A1/A2 
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receptor activation may increase NO synthesis through changes in calcium or potassium fluxes 
(Bryan and Marshall, 1999; Ishibashi, 1998). Adenosine receptors may also be coupled to ATP-
sensitive potassium channels (K+ATP) and have been found to induce NO and vasodilation 
through their actions on these channels (Bryan and Marshall, 1999; Danialou et al. 1997; Hein 
and Kuo, 1999; Marshall et al. 1993; Mubagwa and Flameng, 2001); however, in the context of 
cutaneous active vasodilation, a role for K+ATP channels has not yet been established.  
An additional mechanism by which adenosine receptors may contribute to the NO 
component of reflex vasodilation may include an interaction between adenosine, NO, and 
prostaglandins. Previous studies indicate adenosine may cause vasodilation, at least in part, by 
stimulating release of both NO and prostaglandins from the vascular endothelium, where the 
release of NO caused by the action of adenosine receptors may be prostaglandin dependent 
(Danialou et al. 1998;  Mortensen et al. 2009; Ray and Marshall, 2009). In the context of 
cutaneous active vasodilation, McCord et al. (2006) found that the cylooxygenase pathway, and 
presumably COX-derived prostaglandins, contributes to cutaneous active vasodilation; however, 
this cyclooxygenase contribution was found to be independent of NO. Nevertheless, it is possible 
there is an interaction between prostaglandins and adenosine. 
There is further evidence to suggest an interaction between histamine receptors and 
purinergic (A1/A2) receptors (Dickensen and Hill, 1994) and between NK1 receptors and 
purinergic receptors (Burnstock, 2009; Ralevic, 2009).  Inasmuch as Wong and colleagues 
(2004) and Wong and Minson (2006) have demonstrated that H1 histamine receptor activation 
and NK1 receptor activation, respectively, contributes to cutaneous active vasodilation, it is 
possible the effects of adenosine and adenosine receptor activation during hyperthermia are 
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being manifest through the H1 and NK1 receptor activation components; however, these potential 
interactions awaits further investigation.  
 Limitations 
There are at least three limitations to this study that need to be addressed.  First, as we 
observed no effect of theophylline on cutaneous active vasodilation, it is possible theophylline is 
either ineffective at inhibiting A1/A2 receptors or our concentration of theophylline was 
inadequate.   We have previously demonstrated that during local heating of the skin, adenosine 
receptor activation contributes to the skin blood flow response both directly and through NO 
(Fieger and Wong, 2010).   The cutaneous vasodilation elicited via local heating is, on average, 
greater in magnitude than that achieved with whole body heat stress. In our previous study we 
used a 4 mM concentration, as this was the highest possible concentration that could be used 
without eliciting non-specific vasodilation.  The non-specific vasodilation of theophylline, or the 
similar antagonist, aminophylline, is not exclusive to human skin (Casey et al. 2009) and is most 
likely due to the phosphodiesterase inhibitor properties of these compounds (Taddei et al. 1991).  
Thus, our previous data demonstrating an attenuated cutaneous vascular response to local heating 
with 4 mM theophylline would argue against the notion theophylline is ineffective at inhibiting 
A1/A2 receptors and/or that the concentration used was inadequate.   
Second, we did not directly measure adenosine and, as such, our data do not allow us to 
speak directly as to whether adenosine per se is responsible for the observed A1/A2 component 
when NOS is inhibited.  Shibasaki et al. (2007) and Wingo et al. (2010) have both demonstrated 
2.8 mM adenosine infused into the cutaneous interstitial space via microdialysis elicits 
vasodilation to an extent similar to that achieved during whole body heat stress, suggesting 
adenosine, at relatively low concentrations, is vasoactive in human skin.  Several studies have 
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demonstrated an increase in skeletal muscle adenosine concentration during exercise (Frandsen 
et al. 2000; Hellsten et al. 1998; Mortensen et al. 2009); however, to our knowledge there have 
been no studies measuring changes in interstitial adenosine concentration from human skin.  
Although theoretically possible, a potential technical limitation to recovering and measuring 
adenosine from human cutaneous interstitial fluid is the reported half-life of adenosine which is 
approximately <1 second (Moser et al. 1989).  Inasmuch as peak CVC during heat stress 
requires, on average, approximately 45 minutes in most subjects, it is highly probably that any 
adenosine produced during heat stress would be degraded during recovery of cutaneous 
interstitial dialysate.  
Third, theophylline is a competitive but non-selective inhibitor of A1 and A2 adenosine 
receptors; this does not allow us to determine the specific contribution of the various isoforms of 
adenosine receptors to cutaneous active vasodilation.  Both A1 and A2 adenosine receptors have 
been localized in human skin (Stojanov and Proctor, 1989) and both isoforms have been shown 
to elicit vasodilation (Bryan and Marshall, 1999).  Further, both A1 and A2 isoforms have several 
subtypes (e.g., A2B subtype).  It is difficult to determine and assign specific roles to each isoform 
and subtype as the distribution and mechanism of action is heterogeneous.  For example, 
vasodilation in skeletal muscle during resting, hypoxic conditions has been shown to be due to 
A1 receptor activation (Bryan and Marshall, 1999a,b) whereas A2A receptors are responsible for 
skeletal muscle vasodilation during tetanic contractions (Ray and Marshall, 2009).  In addition, 
Ansari et al. (2007) recently observed that adenosine-mediated vasodilation in the aorta is due to 
A2B receptor activation working, in part, through NO.  Further complicating the matter is that 
selective adenosine receptor antagonists approved for human use are lacking.  As such, we chose 
to use a competitive, but non-specific, A1/A2 adenosine receptor antagonist.  
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Despite the aforementioned limitations, our data suggest a role for A1/A2 adenosine 
receptor activation when NOS is inhibited.  Clearly, future research using isoform-specific 
adenosine receptor antagonists combined with recovery and measurement of interstitial 
adenosine during whole body heat stress is warranted. 
 Conclusion 
Data from this study suggest the primary contribution of A1/A2 adenosine receptor 
activation to cutaneous active vasodilation is to increase the production of NO.  Our data further 
suggest that in the presence of NO, A1/A2 receptor activation does not directly contribute to 
cutaneous active vasodilation; however, a role for A1/A2 receptor activation was unmasked when 
NO synthase was inhibited.  Inhibition of adenosine receptors combined with NO synthase 
inhibition results in a significant attenuation in skin blood flow that is greater than the effect of 
NO synthase inhibition alone, suggesting A1/A2 adenosine receptor activation may be 
responsible for a portion of the known NO component of cutaneous active vasodilation.  
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Appendix A - Informed Consent Form: Mechanisms of Cutaneous 
Thermal Hyperemia in Humans  
This is an important document.  Please read it carefully.  This form explains what you 
need to know about this study.  If you agree to take part in this research study, you need to sign 
this form.  Your signature indicates you have been told about the study and the risks of 
participating in this study have been explained to you.  Your signature on this form also indicates 
that you want to take part in this study. 
Project Title: Mechanisms of Cutaneous Thermal and Reactive Hyperemia in Humans 
 
Primary Investigator: Brett Wong, Ph.D. 
 
Approved by Institutional Review Board (IRB): June 29, 2009 
 
Expiration Date of IRB Approval: June 29, 2011 
 
Protocol Number: 5092 
 
Sponsor of Project: Kansas State University  
 Purpose of This Research Project:  
 The purpose of the research described in this form is twofold.  First, we seek to better 
understand how humans increase blood flow to the skin when mild heat is applied to a small area 
of skin.  When mild heat is applied to the skin there is an increase in skin blood flow that is 
termed “thermal hyperemia”.  The increase in blood flow is a protective mechanism.  The blood 
flow “picks up” the heat and moves it away from the area being heated in order to prevent 
damage to the skin.  Application of mild heat to the skin and observing the ensuing blood flow 
response is frequently used to test the overall health of the blood vessels in a number of 
populations, such as patients with diabetes and cardiovascular disease.  It is also frequently used 
to test blood vessel health in healthy, older individuals.  However, it is still unknown how skin 
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blood flow increases in response to local heat which minimizes the utility of this response as a 
clinical tool.  The first purpose of our research is to better understand how blood flow increases 
to the skin when mild heat is applied to the skin. 
The second goal of this research is to better understand how blood flow to the skin 
increases following a period of arterial occlusion.  Blood flow to a limb, such as the forearm, can 
be occluded (stopped) for a period of time by inflating a blood pressure cuff placed on the upper 
arm.  This stoppage is termed an “arterial occlusion.”  When the cuff pressure is decreased, there 
is a rapid and large increase in blood flow to the limb that is termed “reactive hyperemia.”  This 
response is frequently used to test the overall health of the blood vessels in healthy older humans 
and in patients with diabetes and cardiovascular disease.  However, we do not completely 
understand what causes the increase in blood flow following an arterial occlusion and this limits 
the usefulness of reactive hyperemia as a clinical test of blood vessel health.  We hope to better 
understand how blood flow increases to the skin following an arterial occlusion.  
 Procedures or Methods To Be Used In The Study: 
1. You will arrive at Dr. Wong’s laboratory in room 8B Ahearn Hall in the Department of 
Kinesiology at Kansas State University to participate in the experimental protocol.  This 
testing will take approximately 5 hours to complete.  You will complete a brief health history 
form that will include your age, height, weight, allergies, etc.  You will be instrumented with 
a cuff on your right finger so we can measure your blood pressure and small adhesive patches 
that will be connected to cables so we can monitor your heart rate (electrocardiogram or 
ECG).  You will then be outfitted with a nylon jacket that has small tubing sewn into it.  We 
will pump water through the suit to control your body temperature (you will not get wet).  All 
subjects have the right to have a member of the same sex collect information on the health 
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history form and in the laboratory during data collection.  For female subjects, Sarah Fieger 
is the designated female lab personnel and will be contacted upon your request.  
 
2. You will have 4 small tubes called microdialysis fibers placed in the skin of your forearm.  
These tubes are smaller than the size of a pencil lead.  To place the small tubes, we will first 
numb the area of skin with ice for about 5 minutes.  We will then place a small needle just 
under the surface of your skin in four different locations on your forearm (one needle for 
each of the 4 small tubes).  The small tubes will then be placed inside the needle, the needles 
will be removed, and the small tubes will be left under your skin for the duration of the 
experiment. 
3. We will need to wait approximately 1-2 hours after the insertion of the small tubes to allow 
the insertion trauma (redness of your skin around the small tubes) to go away.  During this 
time, we will place a small probe (laser-Doppler probe) over the skin where the small tubes 
were placed so that we can measure the skin blood flow over the small tubes. 
4. During the experiment, we will inflate the cuff around your right finger to measure your 
blood pressure.  If the cuff inflation becomes uncomfortable at any point, let the investigator 
know and it will be turned off for a few minutes. 
5. We will maintain your body temperature at normal levels by pumping thermoneutral (32°C 
or ~90°F) water through the suit.  This is a temperature of water that should maintain your 
body temperature at normal levels (37°C or ~98.6°F).  We want you to remain comfortable 
(not too hot or too cold) so if the water temperature is too cold or too warm, inform the 
investigator and the temperature will be adjusted accordingly.   
6. You will undergo one of the following experimental procedures (only the one circled): 
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a. “Slow” Local Heating:  Small heaters about the size (diameter) of a quarter will 
be placed on your forearm skin with double sided tape.  The heaters will be set at 
a temperature of 33°C (~91°F), which is the normal temperature of your skin 
when your body temperature is ~98.6°F.  We will slowly increase the temperature 
of the heaters from 33°C (91°F) to 42°C (~108°F) at a rate of 1°C every 10 
minutes.  You may feel a slight warm sensation on your skin but you should not 
feel any pain associated with the heating.  A temperature of 42°C (108°F) is well 
below the temperature that can become painful (~110°F) as well as the 
temperature that can burn the skin (~113°F).  However, if the heating becomes 
painful for even a short period of time, inform one of the investigators and the 
temperature will be lowered or turned off. 
b. “Rapid” Local Heating:  With this procedure, the small heaters will be heated 
from 33°C (91°F) to 42°C (108°F) at a rate of 1°C every 10 seconds.  This 
heating protocol may cause a slight stronger warm sensation on your forearm skin 
but should not cause any sensation of pain.  However, if there is even a brief 
sensation of pain or burning, inform one of the investigators and the temperature 
will be either lowered or turned off. 
c. Reactive Hyperemia: A blood pressure cuff will be placed on your right upper 
arm.  We will stop blood flow to your arm three (3) times for a period of 5 
minutes with at least 10 minutes of recovery between each blood flow occlusion. 
7. During the experimental procedure, we will place very small doses of drugs through the 
small tubes in your skin.  The drugs will cause the blood vessels in your skin to either open 
up or become narrow.  The drugs have been used safely in humans in previous experiments, 
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have been approved and sterilized for human use, and will stay localized in the skin (i.e., the 
microdialysis fiber will prevent the drugs from circulating throughout the body or causing a 
systemic, whole-body effect).  You should not feel anything when the drugs are infused 
through the small tubes.  However, it is possible you may feel a slight tingling sensation in 
the area.  This is normal but you should still inform the investigator. 
You will receive the following drugs in your skin (only the ones circled by the 
investigator): 
a. Sodium Nitroprusside:  This produces a molecule called nitric oxide and causes the blood 
vessels in your skin to open.  This solution is similar to nitroglycerin tablets that patients 
with heart disease place under their tongue when they experience chest pain. 
b. Lactated Ringer’s Solution or Saline Solution:  These are solutions that are used to mimic 
the fluid in your body that surrounds the cells of your skin. 
c. Propylene Glycol or Dimethyl Sulfoxide (DMSO):  This is a solution that is used to 
dissolve some of the drugs that will be infused into your skin.  This solution is commonly 
used to dissolve drugs that are given to patients through an i.v.  DMSO is used similar to 
propylene glycol.  DMSO is frequently used to treat muscle soreness and joint pain in 
athletes. 
d. L-NAME:  This is a drug that will block the production of a molecule called nitric oxide 
and will cause the blood vessels in your skin to close. 
e. Capsazepine or JNJ 17203212:  These are synthetic forms of capsaicin, which is the 
active ingredient in hot chili peppers.  Both compounds will block microscopic openings 
found on sensory nerves in your skin (TRPV-1 receptors).   
f. Calcitonin Gene-Related Peptide (CGRP) & CGRP 8-37:  CGRP is a peptide (short 
protein) that is found in the nerve cells in your skin and in other nerves of your body.  
CGRP will cause your skin vessels to open and increase blood flow. CGRP 8-37 is a 
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fragment (small piece) of the normal CGRP peptide and is used to block the effect of the 
normal CGRP peptide. 
g. Substance P:  This is a peptide (short protein) that is found in the nerve cells in your skin 
and other places in the body. Substance P will cause your skin vessels to open and blood 
flow to increase. 
h. Glibenclamide & PNU 37883:  These are drugs that are often prescribed to diabetic 
patients and blocks small, microscopic openings (called ATP-sensitive potassium 
channels, or K+ATP channels) and may cause your skin vessels to narrow and blood flow 
to decrease. 
i. Theophylline & PSB 1115:  These compounds will be used to block a molecule called 
adenosine, which is naturally produced by your body.  These compounds may cause your 
skin vessels to narrow and blood flow to decrease.  These compounds are similar to 
caffeine. 
j. Rp-cGMPs:  This substance blocks the effects of nitric oxide in your skin and may cause 
the skin vessels to narrow and blood flow to decrease. 
k. Rp-cAMPs:  This substance blocks the effects of CGRP and substance P in your skin and 
may cause your skin blood vessels to narrow and blood flow to decrease.   
l. 8-Br-cGMP & 8-Br-cAMP:  These compounds act similar to nitric oxide (8-Br-cGMP) 
and CGRP and substance P (8-Br-cAMP) and both may cause your blood vessels to open 
and blood flow to increase. 
m. MY-5445 & T 0156:  These compounds are called “phosphodiesterase inhibitors.”  Your 
body naturally destroys nitric oxide to prevent it from working too long.  These 
compounds prevent your body from breaking down nitric oxide.  Sildenafil, or Viagra, is 
the most well-known form of these compounds.  Your skin blood vessels may open and 
blood flow may increase. 
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8. We will heat the area of skin over each microdialysis fiber to 43°C (~109°F).  This will be 
done at the same time sodium nitroprusside is infused.  Both will be done in order to produce 
maximal (100%) blood flow in each area of skin.  This will allow us to present the data as a 
percentage of 100%.  If the temperature is uncomfortable, inform one of the investigators and 
the temperature will be turned down or off. 
9. At the end of the experiment, we will clean the area of the skin where the small tubes are 
located, the tubes will be removed, and a bandage will be placed over the area of skin where 
the tubes were placed. 
 Length of Study:  
You will be in the study for only one day (about 5 hours). 
 Anticipated Risks of The Study: 
1. Skin Microdialysis:  There may be some discomfort during the insertion of the small tubes in 
your skin.  Once the needle is in place, the pain should subside.  Infusions through the fibers 
should not be painful, and there should only be minor swelling at the site.  At the end of the 
study, the fibers will be withdrawn and a sterile dressing will be applied.  Any swelling or 
redness after the study should be gone a few hours after completion of the study.  Although 
the small tubes are sterile, there is a slight risk of infection at the sites where the small tubes 
were placed in your skin.  You will be instructed how to keep the areas clean for a day or two 
following the study.  Risk is considered minimal. 
2. Local Skin Heating: The local skin heaters may cause some minor skin discomfort.  The goal 
is to warm the area of skin to a temperature that has been determined to be below the 
threshold for pain.  If the local heating becomes painful, you should tell the investigator and 
the temperature of the local heater will be lowered.  There is a slight risk of burning the skin 
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at this sight, so it is important that you tell the investigators of any pain you are feeling.  The 
heating device may be removed at any time if you experience any discomfort.  The risks are 
considered to be minimal. 
3. Experiment Drugs: We will be infusing very small doses of each drug, and only into a very 
small area of your skin.  All of the drugs have been approved for use in humans.  You will 
not have any systemic (whole body) effects of these drugs, and they will not alter your blood 
pressure in the small doses given in this study.  There is a minimal risk of an allergic reaction 
to the prescription drugs. 
4. Laser-Doppler Probes: These probes send a small light into your skin.  You will not feel 
anything except the probe touching your skin. There are no major risks associated with this 
procedure. 
5. Blood Pressure Cuff:  In some people, inflation of the blood pressure cuff can become 
uncomfortable.  Many times this is because the cuff has been placed around your finger too 
tightly or because it has been on for a long time.  If the inflation of the blood pressure cuff 
becomes uncomfortable at any time, let the investigator know and they will deflate the cuff 
and check the placement of the cuff on your finger.  There are no major risks associated with 
this device or procedure. 
6. Blood Flow Occlusion:  The inflation of the blood pressure cuff to stop blood flow may 
cause a slight tingling sensation.  The sensations with longer occlusions are similar to the 
sensations when a limb has “fallen asleep.”  If, at any time, you experience any discomfort 
you may request that the blood pressure cuff be either loosened or removed.  When the cuff 
is inflated, you may have the pressure released and the cuff deflated at any time should you 
experience any discomfort.  There are no major risks associated with this procedure.   
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 Anticipated Benefits of This Study:  
This study is done to gather information only and will not benefit your health or fitness.  
However, the information gathered from this study has the potential to help those individuals 
who are most prone to poor blood vessel health, such as the elderly and those with chronic 
diseases (diabetes, cardiovascular disease). 
 Cost of Tests and Procedures: 
You will not need to pay for any tests or procedures that are done for this research study. 
You will be paid at a rate of $10.00 per hour spent in the study.  This money is for the 
inconvenience and time you spent in this study.  If you start the study but stop before the study 
has ended, you will get part of this money. 
 Your Rights If You Decide To Take Part In This Study: 
Taking part in this research study is your decision.  You do not have to take part in this 
study, but if you do, you can stop at any time. Your decision whether or not to participate will 
not affect your relationship with Kansas State University. 
You do not waive any liability rights for personal injury by signing this form.  All forms 
of medical diagnosis and treatment whether routine or experimental, involve some risk of injury.  
In spite of all precautions, you might develop medical complications from participating in this 
study.  Any complications or adverse reactions will be immediately reported to the University 
Research Compliance Office at Kansas State University. 
Kansas State University is not able to neither offer financial compensation nor absorb the 
costs of medical treatment should you be injured as a result of participation in this research.  If 
such complications arise, the researchers will assist you in obtaining appropriate medical 
treatment, which will be provided at the usual charge. 
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The investigators may stop you from taking part in this study at any time if it is in your 
best interest, if you do not follow the study rules, or if the study is stopped.  You will be told of 
important new findings or any changes in the study or procedures that may happen. 
 Extent of Confidentiality:  
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission.  Subject 
identities will be kept confidential by assigning you a “subject identification number”.  The 
names associated with each subject identification number will be kept in a locked file cabinet in 
Dr. Wong’s office.  All files with subject names and identification numbers will be destroyed 
after all data has been collected and analyzed and for a period of one year after the results from 
the study have been published. 
Your social security number (SSN) and mailing will be collected so that you may be paid.  
Your SSN and mailing address is required by Kansas State University to mail you a check for 
your participation in this research.  Your SSN and mailing address will be kept locked in a file 
cabinet until a check has been mailed to you and once it has been verified that you have cashed 
or deposited the check.  Once the check has been mailed and cashed/deposited, your SSN and 
mailing address will be destroyed (shredded). 
 Terms of Participation: 
I understand this project is research and that my participation is completely voluntary.  I 
also understand that if I decide to participate in this study, I may withdraw my consent at any 
time, and stop participating at any time without explanation, penalty, or loss of benefits, or 
academic standing to which I may otherwise be entitled. 
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I verify that my signature below indicates that I have read and understand this consent 
form, and willingly agree to participate in this study under the terms described, and that my 
signature acknowledges that I have received a signed and dated copy of this consent form. 
 
 
Participant Name (Please Print):           
 
 
Signature of Participant:        Date:     
 
 
Signature of Project Staff:        Date:     
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Appendix B - Informed Consent Form: Mechanisms of Cutaneous 
Active Vasodilation 
This is an important document.  Please read it carefully.  This form explains what you 
need to know about this study.  If you agree to take part in this research study, you need to sign 
this form.  Your signature indicates you have been told about the study and the risks of 
participating in this study have been explained to you.  Your signature on this form also indicates 
that you want to take part in this study. 
Project Title:  Sensory Nerves and Histamine Receptors in Cutaneous Active 
Vasodilation in Humans 
Primary Investigator:  Brett Wong, Ph.D. 
Approved by Institutional Review Board (IRB):  20 January 2009 
                        29 June 2009 (revised protocol approved) 
Expiration Date of IRB Approval:   26 February 2012 
Protocol Number:   4547.0 
Sponsor of Project: Kansas State University  
 Purpose of This Research Project:   
The purpose of the research described in this form is to better understand how humans 
increase blood flow to the skin during periods of increased environmental temperatures.  When 
humans are exposed to high environmental temperatures, our internal (core) body temperature 
also increases.  The primary way in which humans defend against large increases in core body 
temperature is to increase blood flow to the skin and to sweat.  The increase in blood flow to the 
skin will move warm blood to the skin where the heat can be released by evaporation of sweat.  
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Although it is clear that increasing skin blood flow during heat stress is important, we do not 
fully understand how humans increase blood flow to the skin. 
 
In order to better understand these problems, we will address the following questions in 
this study: 
• Do transient receptor potential voltage type 1 (TRPV-1) receptors contribute to the rise 
in skin blood flow during heat stress? (TRPV-1 receptors are small, microscopic 
openings located on the nerves in the skin.) 
• Does histamine (a substance released from the cells in your skin and involved in 
seasonal allergies) contribute to the rise in skin blood flow during heat stress and in 
response to locally applied heat? 
• Do sensory nerves in the skin (the nerves that sense itch, heat, cold, etc) contribute to 
the increase in skin blood flow during heat stress? 
 Procedures or Methods To Be Used In The Study: 
You will arrive at Dr. Wong’s laboratory in room 8B Ahearn Hall in the Department of 
Kinesiology at Kansas State University to participate in the experimental protocol.  This testing 
will take approximately 5 hours to complete.  You will complete a brief health history form that 
will include your age, height, weight, allergies, etc.  You will be instrumented with a cuff on 
your right arm so we can measure your blood pressure and small adhesive patches that will be 
connected to cables so we can monitor your heart rate (electrocardiogram or ECG).  You will 
then be outfitted with a nylon suit that has small tubing sewn into it.  We will pump water 
through the suit to control your body temperature (you will not get wet).  All subjects have the 
right to have a member of the same sex collect information on the health history form and in the 
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laboratory during data collection.  For female subjects, Ms. Sarah Fieger is the designated female 
lab personnel and will be contacted upon your request.  
1. You will have 4 small tubes called microdialysis fibers placed in the skin of your forearm.  
These tubes are smaller than the size of a pencil lead.  To place the small tubes, we will first 
numb the area of skin with ice for about 5 minutes.  We will then place a small needle just 
under the surface of your skin in four different locations on your forearm (one needle for 
each of the 4 small tubes).  The small tubes will then be placed inside the needle, the needles 
will be removed, and the small tubes will be left under your skin for the duration of the 
experiment. 
2. We will need to wait approximately 1-2 hours after the insertion of the small tubes to allow 
the insertion trauma (redness of your skin around the small tubes) to go away.  During this 
time, we will place a small probe (laser-Doppler probe) over the skin where the small tubes 
were placed so that we can measure the skin blood flow over the small tubes. 
3. During the experiment, we will periodically inflate the cuff around your right arm to measure 
your blood pressure.  This cuff will only be inflated for about 30 seconds.  However, if the 
cuff inflation becomes uncomfortable at any point, let the investigator know and it will be 
turned off. 
4. We will warm your body by pumping warm water through the nylon suit you are wearing 
until your body temperature is increased from about 98.6°F (normal body temperature) to 
about 101°F.  It will take about 50-70 minutes to increase your body temperature to 101°F.  
To heat your body faster, we will cover your body with a plastic rain suit.  During the heating 
period, we will monitor your heart rate (ECG) and your body temperature and we will 
periodically ask you how you are feeling.  A small temperature-sensing wire will be placed 
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under your tongue to measure your body temperature during the experiment.  At the end of 
the heating period, we will remove the plastic rain suit and pump cool water through the 
nylon suit you are wearing until your body temperature returns to normal. 
5. We will heat a small area of your skin with a small heater to 43°C (about 107°F) to 
maximally open the blood vessels in your skin.  This temperature is below the temperature 
where heating becomes painful (about 110°F) and well below the temperature that may burn 
your skin (about 113°F).  However, if the heater is becoming painful, inform the investigator 
and the temperature will be lowered or the heater turned off. 
6. During the experiment, we will place very small doses of drugs through the small tubes in 
your skin.  The drugs have been used safely in humans in previous experiments, have been 
approved and sterilized for human use, and will stay localized in the skin (i.e., the 
microdialysis fiber will prevent the drugs from circulating throughout the body or causing a 
systemic, whole-body effect).  The drugs will cause the blood vessels in your skin to either 
open up or become narrow.  You should not feel anything when the drugs are infused 
through the small tubes.  However, it is possible you may feel a slight tingling sensation in 
the area.  This is normal but you should still inform the investigator. 
You will receive the following drugs in your skin (only the ones circled by the 
investigator): 
a. EMLA Cream: This is an anesthetic cream that is used to numb a small area of 
your skin.  It will be placed on the surface of the skin and covered with a sterile 
bandage for a period of 1 hour.  After one hour, the bandage will be removed, the 
cream wiped off, and a new application of the cream will be placed on your skin 
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for an additional 1 hour.  This cream is frequently used in clinics and hospitals for 
procedures such as i.v. placement. 
b. Histamine: This is a molecule that is found in cells in your body and is involved 
in seasonal allergies (runny nose, itchy eyes and skin associated with “hay 
fever”).  This will cause the vessels in your skin to open. 
c. Ciproxifan, Clobenpropit, or Thiperamide:  These are drugs that block a form of 
the histamine receptor (H3).  Histamine receptors are involved in seasonal 
allergies (“hay fever”).  Blocking the H3 receptor, which is a microscopic opening 
located on nerves in your skin, may cause your skin blood vessels to narrow. 
d. Pyrilamine: This is a drug that blocks the effects of histamine.  It will prevent the 
vessels of your skin from opening when histamine is present. 
e. Sodium Nitroprusside:  This produces a molecule called nitric oxide and causes 
the blood vessels in your skin to open. 
f. Lactated Ringer’s Solution:  This is a solution that is used to mimic the fluid in your body 
that surrounds the cells of your skin. 
g. L-NAME:  This is a drug that will block the production of a molecule called nitric oxide 
and will cause the blood vessels in your skin to close. 
h. Capsazepine or JNJ 17203212:  These are synthetic forms of capsaicin, which is the 
active ingredient in hot chili peppers.  Both compounds will block microscopic openings 
found on sensory nerves in your skin (TRPV-1 receptors).  
i. Imetit: This will activate the H3 histamine receptor and may cause your skin vessels to 
open. 
j. Yohimbine: This will block small openings on the vessels of your skin and may cause 
them to close. 
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k. Propylene Glycol or Dimethyl Sulfoxide (DMSO):  This is a solution that is used to 
dissolve some of the drugs that will be infused into your skin.  This solution is commonly 
used to dissolve drugs that are given to patients through an i.v.  DMSO is used similar to 
propylene glycol.  DMSO is frequently used to treat muscle soreness and joint pain in 
athletes. 
l. Glibenclamide & PNU 37883:  These are drugs that are often prescribed to diabetic 
patients and blocks small, microscopic openings (called ATP-sensitive potassium 
channels, or K+ATP channels) and may cause your skin vessels to narrow and blood flow 
to decrease. 
m. Theophylline & PSB 1115:  These compounds will be used to block a molecule called 
adenosine, which is naturally produced by your body.  These compounds may cause your 
skin vessels to narrow and blood flow to decrease.  These compounds are similar to 
caffeine. 
n. Rp-cGMPs:  This substance blocks the effects of nitric oxide in your skin and may cause 
the skin vessels to narrow and blood flow to decrease. 
o. Rp-cAMPs:  This substance blocks the effects of CGRP and substance P in your skin and 
may cause your skin blood vessels to narrow and blood flow to decrease.   
p. 8-Br-cGMP & 8-Br-cAMP:  These compounds act similar to nitric oxide (8-Br-cGMP) 
and CGRP and substance P (8-Br-cAMP) and both may cause your blood vessels to open 
and blood flow to increase. 
q. MY-5445 & T 0156:  These compounds are called “phosphodiesterase inhibitors.”  Your 
body naturally destroys nitric oxide to prevent it from working too long.  These 
compounds prevent your body from breaking down nitric oxide.  Sildenafil, or Viagra, is 
the most well-known form of these compounds.  Your skin blood vessels may open and 
blood flow may increase. 
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7. At the end of the experiment, we will clean the area of the skin where the small tubes are 
located, the tubes will be removed, and a bandage will be placed over the area of skin where 
the tubes were placed. 
 Length of Study:  
You will be in the study for only one day (about 5 hours). 
 Anticipated Risks of The Study: 
1. Skin Microdialysis:  There may be some discomfort during the insertion of the small tubes in 
your skin.  Once the needle is in place, the pain should subside.  Infusions through the fibers 
should not be painful, and there should only be minor swelling at the site.  At the end of the 
study, the fibers will be withdrawn and a sterile dressing will be applied.  Any swelling or 
redness after the study should be gone a few hours after completion of the study.  Although 
the small tubes are sterile, there is a slight risk of infection at the sites where the small tubes 
were placed in your skin.  You will be instructed how to keep the areas clean for a day or two 
following the study. 
2. Whole Body Heating: The heat exposure can be physically demanding and can cause light-
headedness, low blood pressure, fatigue, nausea, or cramps.  Therefore, you should keep the 
investigator informed of your feelings and you should not attempt to prolong the heating 
experiment if you do not feel well.  You are free to stop at any time. 
3. Local Skin Heating: The local skin heaters may cause some minor skin discomfort.  The goal 
is to warm the area of skin to a temperature that has been determined to be below the 
threshold for pain.  If the local heating becomes painful, you should tell the investigator and 
the temperature of the local heater will be lowered.  There is a slight risk of burning the skin 
91 
at this sight, so it is important that you tell the investigators of any pain you are feeling.  The 
heating device may be removed at any time if you experience any discomfort. 
4. Experiment Drugs: We will be infusing very small doses of each drug, and only into a very 
small area of your skin.  All of the drugs have been approved for use in humans.  You will 
not have any systemic (whole body) effects of these drugs, and they will not alter your blood 
pressure in the small doses given in this study.  There is a minimal risk of an allergic reaction 
to the prescription drugs. 
5. Laser-Doppler Probes: These probes send a small light into your skin.  You will not feel 
anything except the probe touching your skin. There are no major risks associated with this 
procedure. 
6. Blood Pressure Cuff: In some people, inflation of the blood pressure cuff can become 
uncomfortable.  Many times this is because the cuff has been placed around your arm too 
tightly.  If the inflation of the blood pressure cuff becomes uncomfortable at any time, let the 
investigator know and they will deflate the cuff and check the placement of the cuff on your 
arm.  There are no major risks associated with this device or procedure. 
 Anticipated Benefits of This Study:  
This study is done to gather information only and will not benefit your health or fitness.  
However, the information gathered from this study has the potential to help those individuals 
who are most prone to heat-related illnesses and heat-related deaths, such as the elderly and those 
with chronic diseases (diabetes, cardiovascular disease). 
 Cost of Tests And Procedures: 
You will not need to pay for any tests or procedures that are done for this research study. 
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You will be paid at a rate of $10.00 per hour spent in the study.  This money is for the 
inconvenience and time you spent in this study.  If you start the study but stop before the study 
has ended, you will get part of this money. 
 Your Rights If You Decide To Take Part In This Study: 
Taking part in this research study is your decision.  You do not have to take part in this 
study, but if you do, you can stop at any time. Your decision whether or not to participate will 
not affect your relationship with Kansas State University. 
You do not waive any liability rights for personal injury by signing this form.  All forms 
of medical diagnosis and treatment whether routine or experimental, involve some risk of injury.  
In spite of all precautions, you might develop medical complications from participating in this 
study.  Any complications or adverse reactions will be immediately reported to the University 
Research Compliance Office at Kansas State University. 
Kansas State University is not able to neither offer financial compensation nor absorb the 
costs of medical treatment should you be injured as a result of participation in this research.  If 
such complications arise, the researchers will assist you in obtaining appropriate medical 
treatment, which will be provided at the usual charge. 
The investigators may stop you from taking part in this study at any time if it is in your 
best interest, if you do not follow the study rules, or if the study is stopped.  You will be told of 
important new findings or any changes in the study or procedures that may happen. 
 Extent of Confidentiality:  
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. Subject 
identities will be kept confidential by assigning you a “subject identification number”.  The 
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names associated with each subject identification number will be kept in a locked file cabinet in 
Dr. Wong’s office.  All files with subject names and identification numbers will be destroyed 
after all data has been collected and analyzed and for a period of one year after the results from 
the study have been published. 
 Terms of Participation: 
I understand this project is research and that my participation is completely voluntary.  I 
also understand that if I decide to participate in this study, I may withdraw my consent at any 
time, and stop participating at any time without explanation, penalty, or loss of benefits, or 
academic standing to which I may otherwise be entitled. 
I verify that my signature below indicates that I have read and understand this consent 
form, and willingly agree to participate in this study under the terms described, and that my 
signature acknowledges that I have received a signed and dated copy of this consent form. 
 
Participant Name (Please Print):           
 
Signature of Participant:        Date:     
 
Signature of Project Staff:        Date:     
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Appendix C - Proof of Copyright Clearance 
  This is a License Agreement between Sarah M Fieger ("You") and John Wiley and Sons 
("John Wiley and Sons") provided by Copyright Clearance Center ("CCC"). The license 
consists of your order details, the terms and conditions provided by John Wiley and Sons, and 
the payment terms and conditions. 
 License Number: 2615980173115 
 
License date: Feb 25, 2011 
 
Licensed content publisher: John Wiley and Sons 
 
Licensed content publication: Experimental Physiology 
 
Licensed content title Adenosine receptor inhibition with theophylline attenuates the skin 
blood flow   response to local heating in humans  
Licensed content author: Sarah M. Fieger, Brett J. Wong 
 
Licensed content date: Sep 1, 2010 
 
Start page: 946 
 
End page: 954 
 
Type of use: Dissertation/Thesis 
  
Requestor type: Author of this Wiley article 
 
  
                                            Terms and Conditions  
1. The materials you have requested permission to reproduce (the "Materials") are protected 
by copyright.  
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2. You are hereby granted a personal, non-exclusive, non-sublicensable, non-transferable, 
worldwide, limited license to reproduce the Materials for the purpose specified in the licensing 
process. This license is for a one-time use only with a maximum distribution equal to the 
number that you identified in the licensing process. Any form of republication granted by this 
licence must be completed within two years of the date of the grant of this licence (although 
copies prepared before may be distributed thereafter). The Materials shall not be used in any 
other manner or for any other purpose. Permission is granted subject to an appropriate 
acknowledgement given to the author, title of the material/book/journal and the publisher and 
on the understanding that nowhere in the text is a previously published source acknowledged 
for all or part of this Material. Any third party material is expressly excluded from this 
permission. 
3. With respect to the Materials, all rights are reserved. Except as expressly granted by the 
terms of the license, no part of the Materials may be copied, modified, adapted (except for 
minor reformatting required by the new Publication), translated, reproduced, transferred or 
distributed, in any form or by any means, and no derivative works may be made based on the 
Materials without the prior permission of the respective copyright owner. You may not alter, 
remove or suppress in any manner any copyright, trademark or other notices displayed by the 
Materials. You may not license, rent, sell, loan, lease, pledge, offer as security, transfer or 
assign the Materials, or any of the rights granted to you hereunder to any other person. 
4. The Materials and all of the intellectual property rights therein shall at all times remain the 
exclusive property of John Wiley & Sons Inc or one of its related companies (WILEY) or their 
respective licensors, and your interest therein is only that of having possession of and the right 
to reproduce the Materials pursuant to Section 2 herein during the continuance of this 
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Agreement. You agree that you own no right, title or interest in or to the Materials or any of 
the intellectual property rights therein. You shall have no rights hereunder other than the 
license as provided for above in Section 2. No right, license or interest to any trademark, trade 
name, service mark or other branding ("Marks") of WILEY or its licensors is granted 
hereunder, and you agree that you shall not assert any such right, license or interest with 
respect thereto. 
5. Neither wiley nor its licensors makes any warranty or representation of any kind to you or 
any third party, express, implied or statutory, with respect to the materials or the accuracy of 
any information contained in the materials, including, without limitation, any implied 
warranty of merchantability, accuracy, satisfactory quality, fitness for a particular purpose, 
usability, integration or non-infringement and all such warranties are hereby excluded by 
wiley and its licensors and waived by you. 
6. WILEY shall have the right to terminate this Agreement immediately upon breach of this 
Agreement by you.  
7. You shall indemnify, defend and hold harmless WILEY, its Licensors and their respective 
directors, officers, agents and employees, from and against any actual or threatened claims, 
demands, causes of action or proceedings arising from any breach of this Agreement by you.  
8. In no event shall wiley or its licensors be liable to you or any other party or any other 
person or entity for any special, consequential, incidental, indirect, exemplary or punitive 
damages, however caused, arising out of or in connection with the downloading, provisioning, 
viewing or use of the materials regardless of the form of action, whether for breach of 
contract, breach of warranty, tort, negligence, infringement or otherwise (including, without 
limitation, damages based on loss of profits, data, files, use, business opportunity or claims of 
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third parties), and whether or not the party has been advised of the possibility of such 
damages. This limitation shall apply notwithstanding any failure of essential purpose of any 
limited remedy provided herein.  
9. Should any provision of this Agreement be held by a court of competent jurisdiction to be 
illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve as nearly 
as possible the same economic effect as the original provision, and the legality, validity and 
enforceability of the remaining provisions of this Agreement shall not be affected or impaired 
thereby.  
10. The failure of either party to enforce any term or condition of this Agreement shall not 
constitute a waiver of either party's right to enforce each and every term and condition of this 
Agreement. No breach under this agreement shall be deemed waived or excused by either 
party unless such waiver or consent is in writing signed by the party granting such waiver or 
consent. The waiver by or consent of a party to a breach of any provision of this Agreement 
shall not operate or be construed as a waiver of or consent to any other or subsequent breach 
by such other party.  
11. This Agreement may not be assigned (including by operation of law or otherwise) by you 
without WILEY's prior written consent.  
12. Any fee required for this permission shall be non-refundable after thirty (30) days from 
receipt.  
13. These terms and conditions together with CCC’s Billing and Payment terms and 
conditions (which are incorporated herein) form the entire agreement between you and 
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes all prior 
agreements and representations of the parties, oral or written. This Agreement may not be 
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amended except in writing signed by both parties. This Agreement shall be binding upon and 
inure to the benefit of the parties' successors, legal representatives, and authorized assigns.  
14. In the event of any conflict between your obligations established by these terms and 
conditions and those established by CCC’s Billing and Payment terms and conditions, these 
terms and conditions shall prevail.  
15. WILEY expressly reserves all rights not specifically granted in the combination of (i) the 
license details provided by you and accepted in the course of this licensing transaction, (ii) 
these terms and conditions and (iii) CCC’s Billing and Payment terms and conditions.  
16. This Agreement will be void if the Type of Use, Format, Circulation, or Requestor Type 
was misrepresented during the licensing process.  
17. This Agreement shall be governed by and construed in accordance with the laws of the 
State of New York, USA, without regards to such state’s conflict of law rules. Any legal 
action, suit or proceeding arising out of or relating to these Terms and Conditions or the 
breach thereof shall be instituted in a court of competent jurisdiction in New York County in 
the State of New York in the United States of America and each party hereby consents and 
submits to the personal jurisdiction of such court, waives any objection to venue in such court 
and consents to service of process by registered or certified mail, return receipt requested, at 
the last known address of such party.  
 
   
  
 
 
 
